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ABBREVIATIONS 
 
Apo  apolipoprotein 
ABC  adenosine triphosphate-binding cassette transporter  
ALT  alanine aminotransferase (= glutamic pyruvic transaminase: GPT) 
AST   aspartate aminotransferase (= glutamic oxaloacetic transaminase: GOT) 
BMI  body mass index (kg/m2) 
CHD  coronary heart disease  
CT  computed tomography  
CVD  cardiovascular disease 
DAG  diacylglycerol  
FDA   Food and Drug Administration 
FOSHU  Food for Specified Health Uses 
γ-GTP  γ-glutamyltranspeptidase 
HDL  high-density lipoprotein 
HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A 
LDL  low-density lipoprotein 
Lp(a)  lipoprotein(a) 
NPC1L1 Nieman-Pick C1 Like 1 
PS  phytosterols (plant sterols, sterol esters, stanols and stanol esters) 
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RLP  remnant-like lipoprotein 
SD  standard deviation 
SE  standard error  
SFA  subcutaneous fat area 
TAG  triacylglycerol  
TBA  total bile acid 
TFA  total fat area 
VFA  visceral fat area 
VLDL  very low-density lipoprotein 
WHO   World Health Organization  
 
To convert for cholesterol from SI unit (mmol/L) to mg/dL, multiply by 1/0.02586 (= 38.67). 
To convert for triacylglycerol from SI unit (mmol/L) to mg/dL, multiply by 1/0.01129 (= 88.57).  
To convert for glucose from SI unit (mmol/L) to mg/dL, multiply by 1/0.05551 (= 18.0).  
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CHAPTER 1 
 
General introduction 
 
In 21st century society, cardiovascular disease (CVD) represents a growing threat to global health. 
According to WHO (2011), the mortality due to CVD in the world that is silently progressive in the 
heart and brain reached approximately one in three people (Fig. 1-1). Several epidemiological studies 
have identified elevated blood cholesterol as a strong risk factor for CVD (Key, 1970; Kannel et al., 
1971; Martin et al., 1986). Low-density lipoprotein (LDL) is a main transporter of cholesterol, but 
readily oxidizes and deposits plaques on artery walls, triggering an ischemic heart attack or stroke. 
Nowadays, cholesterol-lowering medication (e.g., statin) has been established as an effective therapy 
for the prevention of CVD (Shepherd et al., 1995; Downs et al., 1998; 4S Group, 1994; Sacks et al., 
1996; LIPID study Group, 1998; Nakamura et al., 2006).  
Recently, contributions of dietary factors to blood cholesterol concentration are estimated in 
the U.S., (Grundy, 2016). Current dietary cholesterol (Key et al., 1965; Hopkins 1992; Berger et al., 
2015), overnutrition (obesity) and low intake of dietary fiber (Chandalia et al., 2000) raise blood 
cholesterol concentrations by 5%, 5% and 5%, respectively, compared to that of recommended 
intakes. Also, dietary saturated & trans fatty acids found in animal fat, shortening, and deep-fried 
foods (Mustad et al., 1997; Mensink & Katan, 1990) raise blood cholesterol concentration by 10%. 
Meanwhile, a limitation of individual dietary intakes of cholesterol and animal fat can help reduce 
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blood LDL cholesterol concentration by up to 40% and slow or even reverse atherosclerosis (Ornish 
et al., 1998). Also, moderately lowering blood cholesterol by 10% contributes to a reduction in the 
incidence of heart disease in men within 5 years by 50% at age 40 and 20% at age 70 (Law et al., 
1994), however changing eating habits is very hard in this age of plenty. Hence, universally accepted 
‘functional food’ that provides a lifetime of a healthy blood cholesterol should be explored to prevent 
CVD. 
In Japan, the concept of ‘functional food’ comprised of 1) nutritional function, 2) sensory 
function such as flavor and texture, and 3) physiological function was systematically defined early in 
the 1980s (Arai, 1996). The Japanese Ministry of Health, Labour, and Welfare (MHLW) established 
‘Foods for Specified Health Use’ (FOSHU) in 1991 as a regulatory system to approve the health 
claims based on the scientific evidence of the food on the human body. Nowadays, the market of 
FOSHU pass the US$ 6 billion mark (≥ 1,100 items in 2017). Most of the statements of the Japanese 
FOSHU are similar to the structure/function claims in the U.S. or the enhanced function claims of the 
Codex. The concrete evidence including mechanism and responsiveness of the functional foods is 
crucial as well as that of medicines. To extend the human health span, clinical data on the functional 
foods should be verified in different populations. Additionally, a great deal of thought should be given 
to the real effectiveness of physiological function, as well as basic food features such as nutritional and 
sensory functions, in a daily practical field. 
Sterols are universally present in animal and plant kingdoms, not most bacteria and viruses. 
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Cholesterol is a vital element in the cell membrane and as precursor of steroid hormones, vitamin D 
and bile salts, in humans. In general, people gain cholesterol from animal foodstuff (∼300-500 
mg/day) and from de novo synthesis (∼700-1,000 mg/day). By contrast, phytosterols (PS) have 
similar chemical structures to cholesterol (Fig. 1-2), and function in the cell membrane like cholesterol. 
Dietary PS intake from fruits, vegetables and nuts is ∼150- 400 mg/day (Hirai et al., 1986; Katan et al., 
2003); ∼1-1.4 g/day in a vegetarian diet resembling our early ancestral diets (Jenkins et al., 2001).  
Accumulating evidence collected over the last half century indicates that PS consisting of 
∆5-type (‘sterols’) or 5α-reduced type (‘stanols’) help reduce blood cholesterol concentration. PS 
potentially inhibit the intestinal absorption of both dietary and biliary cholesterols by displacing 
cholesterol from micelles, facilitating the excretion of cholesterol in the feces (Fig. 1-3). Daily amount 
of PS intake is near to that of cholesterol, whereas PS are poorly absorbed via intestinal transporters 
including Niemann-Pick C1 Like 1 (NPC1L1) (Altmann et al., 2004) and adenosine 
triphosphate-binding cassette (ABC) G5 and ABCG8 (Berge et al., 2000). In general, conventionally 
purified plant edible oils contain small amount of PS (<1%). Food and drink manufactures have 
developed a variety of foods and drinks (e.g., margarine and milk) enriched with PS extracted from 
soybean oil or tall oil. The US National Cholesterol Education Program Adult Treatment Panel III 
(NCEP, 2002) endorses PS (2 g/day) as an essential feature of a therapeutic lifestyle change along 
with diet modifications, weight reduction, intake of viscous fibers, and increased physical activity to 
reduce the risk of coronary heart disease. Meanwhile, because such high dose of PS may decrease the 
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absorption of fat-soluble vitamins and carotenoids, intakes of fruits and vegetables are recommended. 
To attain the secure cholesterol-lowering effect of PS, it is needed to explore an effectively active 
form of PS even at low-dose (< 1 g/day) especially in Asian with less information than Caucasian.   
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Fig. 1-1  Distribution of major causes of death including CVD 
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Fig. 1-2  Chemical structure of cholesterol and PS 
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Fig. 1-3  Transport of cholesterol (C) and phytosterols (PS) from the intestinal lumen. 
Dietary C and PS mix with biliary C from the gallbladder and form micelles in the intestinal lumen. Specific 
transporters, Nieman-Pick C1 Like 1 (NPC1L1), transport the majority of C and PS into the enterocyte. Then, 
nearly all of the PS turn back to the intestinal lumen by adenosine triphosphate-binding cassette (ABC) 
transporter G5 and ABCG8 for excretion from the body. Some C may also turn back into the intestinal lumen 
by ABCG5/G8. About half of the C is packaged into chylomicrons and are delivered to the liver through the 
lymphatic system and the bloodstream. 
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More recently, modern sedentary habits accompanied with consuming high-fat diets and 
overeating contribute to the epidemic of obesity (WHO, 2011). Especially, visceral fat obesity 
(Matsuzawa et al., 1987), namely augmented intra-abdominal adipose tissue, is recognized to be a 
leading cause for metabolic syndrome (Kissebah et al., 1982; Reaven, 1988; Kaplan, 1989; Grundy et 
al., 2005; JMSDCC, 2005; IDF, 2006), which is a cluster of multiple cardiovascular risk factors such 
as dyslipidemia (Zilversmit, 1979), hypertension (Hayashi et al., 2004), and glucose intolerance 
(Hayashi et al., 2003) linked to type 2 diabetes (Boyko et al., 2000) and CVD (Fujimoto et al., 1999). 
Then, the prevalence of lifestyle-related diseases has encouraged the food industry to develop new 
functional fatty acids (e.g., medium chain-rich triacylglycerol) or non-absorbed fats and oils.  
Diacylglycerol (DAG) is a partial hydrolysate of triacylglycerol (TAG), and naturally occurs 
in edible oils and fats (Abdel-Nabey et al., 1992; D'alonzo et al., 1982), as shown in Table 1-1. In the 
Mediterranean area, olive oil has been consumed for a long time period. It was reported that some 
traditional olive oils obtained in Majorca in Spain contained high DAG content (~20 mol%) (Barceló 
Mairata & Barceló Mairata, 1985). DAG is classified as glycerol positional isomers (1,3:1,2-isomer 
ratio is 7:3), as shown in Fig. 1-4, and is also a component of popular food emulsifiers; however, its 
nutrition was poorly understood. Then, through devoted studies over the quarter of a century, it has 
been demonstrated that DAG oil (≥ 80 wt%) has the taste, texture and energy value of ordinarily used 
TAG oils, as shown in Table 1-2 (Nishide et al., 2004; Taguchi et al., 2001). The major amount of 
DAG in the DAG oil is the 1,3-configuration, not the 1(3),2- configuration (the ratio of 1,3-DAG to 
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1(3),2-DAG was approximately 7:3). The cooking properties (Katsuta et al., 2008; Nakatsugawa et al., 
2001; Ohno, 2002; Ohno, 2003) and sensory evaluation (Ogawa et al., 2001a; Ogawa et al., 2001b) of 
DAG oil were studied compared to those of TAG oil, resulting in almost same between oils. 
Basically, lipases secreted in the intestinal lumen hydrolize dietary TAG to free fatty acids 
and 2-monoacylglycerol (MAG). 2-MAG is absorbed by enterocytes and resynthesized back to TAG. 
Then, most of the TAG generated in the small intestine is secreted as chylomicron particle. The most 
latest research has found out that main 1,3-DAG isomer in DAG is hydrolyzed to 1-MAG or 3-MAG 
in the gut, not 2-MAG like TAG (Kondo et al., 2003). Consequently, since 1-MAG or 3-MAG is not 
effectively utilized to reproduce TAG (chylomicron) in epithelial cells of the small intestine by DGAT, 
DAG oil is less likely to increase postprandial responses of TAG (Tada et al., 2005) and fasting TAG 
concentration in the blood (Yamamoto et al., 2006), and be stored as body fat via the enhanced fat 
oxidation (Nagao et al., 2000), compared to TAG oil. Thus, the metabolism of DAG oil differs from 
those of TAG oil (Fig. 1-5). Then, the Ministry of Health, Labour and Welfare of Japan has approved 
DAG cooking oils as a FOSHU in 1999.  
Furthermore, it was found that because of the basic physiochemical (amphipathic) 
properties, DAG oil could also dissolve free forms of PS much more easily than TAG oil, as shown in 
Fig. 1-6. Maximum solubility of PS is 〜6% in TAG oil vs. 〜1.3% in DAG oil, respectively 
(Meguro et al., 2001). Recent short-term studies indicate that PS-rich DAG oil has enhanced 
cholesterol-lowering activity compared to PS-rich TAG oil (Goto et al., 1999; Meguro et al., 2001; 
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Saito et al., 2006a), suggesting DAG oil works as an advantageous delivery vehicle for PS (Table 1-3). 
Also, the free forms of PS are more economical and lower in calories than ester forms of PS (PSE). 
Therefore, PS-rich DAG oil enriched with two active ingredients that are originally contained at low 
levels in natural plant fats and oils, respectively, may be new advanced functional edible oil with 
multiple health benefits.  
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Table 1-1  Contents of acylglycerols in various edible oils (wt%) 
Edible oils TAG DAG MAG Others 
Soybean oil  97.9 1.0 - 1.1 
Palm oil 93.1 5.8 - 1.1 
Cottonseed oil 87.0 9.5 0.2 3.3 
Corn oil 95.8 2.8 - 1.4 
Safflower oil 96.0 2.1 - 1.9 
Olive oil 93.3 5.5 0.2 1.0 
Rapeseed oil 96.8 0.8 0.1 2.3 
Cocoa butter 96.0 2.2 0.2 1.5 
Tallow 89.6 3.8 - 6.6 
Lard 97.9 1.3 - 0.8 
Oils contain triacylglycerol, TAG; diacylglycerol, DAG; monoacylglycerol, MAG. 
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Table 1-2  Chemical and biological properties between TAG and DAG oils (wt%) 
 TAG oil DAG oil 
Acylglycerol (wt%)   
TAG 97.2 10.7 
DAG  1.1 87.0 
1(or 3), 2-DAG  ND 27.8 
  1,3-DAG ND 59.2 
MAG < 0.05 0.82 
Free fatty acid ND ND 
Fatty acid composition (wt%)   
C16:0  6.0  2.4 
C18:0  2.2  0.7 
C18:1 29.1 28.0 
C18:2 57.8 60.3 
C18:3  2.5  5.6 
C20:0  0.4 < 0.05 
C20:1  0.6  0.2 
C22:0  0.3 < 0.05 
C22:1  0.2 < 0.05 
C24:1  0.2 < 0.05 
Others  0.7  2.8 
Energy value (kJ/g oil) * 39.6 38.9 
Fat absorption coefficient (%) ** 96.3 ± 0.3 96.3 ± 0.4 
Oils contain triacylglycerol, TAG; diacylglycerol, DAG; monoacylglycerol, MAG. 
* Energy values of TAG and DAG oils were measured by bomb calorimeter.  
** Fat intake and excretion in rats fed either TAG or DAG diets for 3days were analyzed (mean ± SEM). 
 
 
 
 
 
 13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-4  Stereospecific isomers of DAG 
  
CH2OCOR1
C
CH2OH
H
sn-1,2-Diacylglycerol
R2OCO
CH2OCOR1
C
CH2OH
H
sn-2,3-Diacylglycerol
R2OCO
CH2OCOR2
C H
sn-1,3-Diacylglycerol
HO
CH2OCOR1
 14 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-5  Possible metabolic fate of TAG and DAG in the small intestine. 
         MGAT: monoacylglycerol O-acyltransferase, DGAT: diacylglycerol O-acyltransferase  
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Fig. 1-6  Solubility of PS (4 wt%) in DAG oil [A] and TAG oil [B], respectively 
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Table 1-3  Dose differences of PS between DAG oil and TAG oil 
Articles 
Dose of PS 
 (as free form g/day) 
Types of PS Solvent 
Goto et al. (1999)  0.4 PSfree / edible oil DAG (dissolved) 
Saito et al. (2006a) 0.4 PSE / mayonnaise DAG (dissolved) 
Meguro et al. (2001) 0.5 PSfree / mayonnaise DAG (dissolved) 
Vanhanen et al. (1992) 0.63 PSE /mayonnaise TAG (dissolved) 
Miettinen et al. (1994) 0.7 PSfree / mayonnaise TAG (dissolved) 
Pelletier et al. (1995) 0.74 PSfree / butter TAG (dissolved) 
Hendriks et al. (1999) 0.83-3.24 PSE/ spread TAG (dissolved) 
Weststrate et al. (1998) 1.6-3.3 PSE / margarine TAG (dissolved) 
Jones et al. (2000) 1.84 PSE / margarine TAG (dissolved) 
Main oils are triacylglycerol: TAG, or diacylglycerol: DAG. 
PS belong to free forms of phytosterols: PSfree or ester forms of phytosterols: PSE.  
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Here, this thesis presents that replacing common TAG oil with PS/DAG oil (PS: 4 wt%) in 
a daily diet was simple and safe, and may therefore be a useful dietary approach to prevent CVD in 
the high cholesterol and/or overweight/obese populations associated with modern diet, unfavorable 
lifestyle, aging, and genetic background. Chapter 2 shows that long-term ad libitum consumption of 
PS/DAG cooking oil without dietary restriction resulted in a robust cholesterol-lowering effect 
throughout the test period, without rebound phenomena or adverse effects, in subjects with moderate 
to hypercholesterolemia. No significant effect was observed in subjects with normocholesterolemia 
(Takeshita et al., 2001). This suggests that practical use of PS/DAG oil will support a long-term 
strategy for the prevention of CVD. Chapter 3 shows that the 4-week PS/DAG cooking oil 
consumption reduced elevated atherogenic blood LDL cholesterol and Lp(a) concentrations in 
postmenopausal women (Takeshita et al., 2007a). These findings suggest that PS/DAG oil has also 
potential benefits for reducing risk factors for CVD even in age-related hypercholesterolemia due to 
estrogen depletion. Chapter 4 discusses the effects of well-regulated consumption of DAG oil or 
PS/DAG oil as a mayonnaise-type food on body fat accumulation and blood lipids in 
overweight/obese middle-aged men. Interestingly, consumption of DAG oil alone slightly, but 
significantly, reduced blood LDL cholesterol concentrations depending on a reduction in abdominal 
fat. Thus, combined consumption of dietary DAG oil with PS may exert mutually complementary 
cholesterol-lowering effects, respectively (Takeshita et al., 2007b). These findings suggest that DAG 
oil functions not only as an advantageous delivery vehicle for PS, but also as an antiatherogenic 
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ingredient mainly in a population with metabolic syndrome. Chapter 5 shows that the consumption of 
PS/DAG cooking oil reinforced low-dose therapy of a major hypocholesterolemic agent, statin 
(cholesterol biosynthesis inhibitors) in persistent hypercholesterolemic outpatients (Takeshita et al., 
2008). This finding suggests that the use of PS/DAG cooking oil in combination with a conservatively 
low dose of statin may play more beneficial role for the prevention of CVD than statin monotherapy 
in hypercholesterolemic patients with a low response to statin due to increased cholesterol absorption.  
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CHAPTER 2 
 
Effectiveness and safety of long-term ad libitum consumption of 
dietary phytosterol-rich diacylglycerol oil 
 
2.1  Introduction 
 
A lifetime of healthy blood cholesterol concentration is a key strategy in the prevention of CVD (Law 
et al., 1994; Ference et al., 2012). Also, the management of other atherosclerotic parameters are very 
important. On the other hand, PS-rich DAG oil may synergistically induce a transient 
cholesterol-lowering effect (400 mg/day) (Goto et al., 1999; Saito et al., 2006a) due to a good vehicle 
for PS, but it is not known whether the addition of PS/DAG oil to the daily diet will ensure the 
long-term maintenance of lowered blood cholesterol concentrations.  
This chapter discusses the effects of 6-month ad libitum consumption of PS/DAG cooking 
oil without dietary restriction on mainly blood lipids. It was demonstrated that the sufficient use of 
PS/DAG oil resulted in a robust cholesterol-lowering effect throughout the test period, without 
rebound phenomena or adverse effects, in subjects with moderate to hypercholesterolemia. No 
significant effect was observed in subjects with normocholesterolemia. These findings suggest that the 
practically daily use of PS/DAG oil will support a long-term strategy for the primary prevention of 
CVD. 
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2.2  Material and methods 
 
Study design 
The study design is presented in Fig. 2-1. During the first -1 month of the run-in period, subjects 
consumed TAG cooking oil. Then, at the beginning of 6-month test period, subjects replaced their 
dietary TAG cooking oil with PS/DAG cooking oil and consumed only PS/DAG cooking oil for the 
subsequent 6 months. All subjects were informed of the study procedures and requirements and gave 
written consent to participate. The study was approved by the Ethics Committee of the Kao 
Corporation, and was conducted according to the Declaration of Helsinki under the supervision of an 
occupational health physician 
 
Subjects 
Seventy-one healthy male and female volunteers with no history of coronary heart disease (CHD) or 
strokes were recruited for the study in the Kao Corporation in Japan, who were 20-year-old and over.  
 
Experimental methods 
Subjects were encouraged to purchase their lunches in the company cafeteria where the experimental 
cooking oil (PS/DAG oil) was used exclusively for weekday meal preparation up before the last +1 
month of the wash-out period at which time TAG cooking oil was again used. Subjects were also 
asked to maintain their normal lifestyles and dietary patterns without dietary restriction, and to 
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consume assigned oils in the form of cooking oil during the entire study period. On the day prior to 
blood sampling, all subjects were instructed to finish dinner by 9:00 pm, to not consume anything 
other than water after this time, and to abstain from alcohol for the 24 hours. A fasting blood sample 
was obtained prior to breakfast. As shown in Fig. 2-1, fasting blood sampling and physical 
measurements were performed at 6 separate time points: -1 month before the test period, at 0 
(baseline), 1, 3, and 6 months during the test period, and +1 month after the wash-out. Total energy 
and intake levels of fat, carbohydrate, protein, fiber, cholesterol, and cooking oil were calculated from 
a diet diary in which subjects recorded dietary intake for 3 consecutive days prior to blood draws at 
the 0-, 1-, 3-, 6-, and +1-week time points. Calculations were performed at the Health & Nutrition 
Institute Snow Brand Milk Products Co., Ltd. based on the 4th Revision of Standard Tables of Food 
Composition in Japan (JST, 1998).  
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Fig. 2-1  Diagram of the study design 
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Test oil 
 DAG rich cooking oil (DAG oil) with an 84 % weight was prepared from soybean oil 
under the immobilized lipase according to the method of Huge-Jensen et al. (1988). The ratio of 
1,3-DAG to 1(3),2-DAG in DAG oil was 66:34 wt/wt. The major fatty acids of DAG oil were oleic 
acid and linoleic acid (C14:0, 0.1; C16:0, 2.5; C18:0, 0.7; C18:1, 28.1; C18:2, 61.1, C18:3, 7.3; 
C20:0, 0.1; C20:1, 0.1 wt%). PS purified from the distillates of soybean and rapeseed oils was 
dissolved in DAG oil at a ratio of 4:96 (wt:wt). One hundred grams of the experimental oil contained 
β-sitosterol 1.85 g, campesterol 1.01 g, stigmasterol 1.20 g, and brassicasterol 0.11 g.  
 
Blood Analyses and anthropometetry measurements 
Plasma and serum were obtained by centrifugation at 1,500 ×g for 15 minutes at 4°C and stored at 
4°C or -80°C, and then analyzed by SRL, Inc. (Tokyo, Japan). Serum triacylglycerol concentrations 
were measured using an LPL-GK-GPO-POD assay kit (Pure Auto S TG-N, Daiichi Pure Chemicals, 
Tokyo, Japan). Serum total cholesterol concentrations were measured using an enzyme assay kit 
(L-type Wako CHO H, Wako Pure Chemical Industries, Osaka, Japan). Serum HDL cholesterol 
concentrations were measured using an enzymatic assay kit (Cholestest N HDL, Daiichi Pure 
Chemicals, Tokyo, Japan). Serum LDL cholesterol concentrations were calculated using 
Friedewald's equation (LDL cholesterol = total cholesterol - HDL cholesterol - triacylglycerol x 0.2; 
0.16 was used instead of 0.2 in cases where serum triacylglycerol was over 400 mg/dl). Serum 
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remnant-like lipoprotein particles cholesterol (RLP-C) concentrations, in a serum lipoprotein fraction 
binding neither to anti-human apo-B100 antibody nor anti-human apo-A1 antibody, were measured 
using a RLP-Cholesterol Immunoseparation Assay Kit (RLP Cholesterol JIMROII, Japan 
Immunoresearch Laboratories Co., Ltd., Gunma, Japan). Serum apolipoprotein (apo) AI, and B 
concentrations were measured using a kit (Auto･N KIT series, Daiichi Pure Chemicals Co., Ltd., 
Tokyo, Japan). Plasma PAI-1 concentrations were measured using an immunoreaction kit (LPIA･
tPAI test, Mitsubishi Kagaku Medical, Inc., Ibaraki, Japan). Serum leptin concentrations were 
measured using a Human Leptin Radioimmunoassay kit (HUMAN LEPTIN RIA KIT, LINCO 
Research, Inc., Missouri, USA). Hematological variables were measured by routine clinical 
techniques (SE-9000, Sysmex Corporation, Hyogo, Japan). Serum phospholipids (PL) 
concentrations were measured using a kit (L-type Wako Phospholipids, Wako Pure Chemical 
Industries, Osaka, Japan). Serum non-esterified fatty acid (NEFA) concentrations were measured 
using an ACS-ACOD-POD assay kit (NEFA-SS ”EIKEN”, Eiken Chemical, Tokyo, Japan). Serum 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities were measured 
using enzymatic assay kits (Transaminase-HR II, Wako Pure Chemical Industry, Osaka, Japan). 
Serum γ-glutamyltranspeptidase (γ-GTP) activity was measured using an enzymatic assay kit 
(Cicaliquid gamma-GT J, Kanto Chemical, Tokyo, Japan). Serum campesterol, β-sitosterol, and 
lathosterol concentrations were analyzed at Kao using gas-liquid chromatography on DB-5ht 
columns (15 m × 0.25mm, J&W Co.) from saponified serum extract as trimethylsilyl derivatives for 
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subjects with serum stocks -80°C (n = 66). These sterols were quantified from a single run using 
5α-cholestane as the internal standard (Gylling et al., 1999). Anthropometric measurements were 
performed immediately before blood sampling to assess body weight, body mass index (BMI), waist 
circumference, hip circumference, and subcutaneous fat thickness using a slide caliper. Subcutaneous 
fat thickness was estimated by adding the upper arm and dorsal fat measurements. 
 
Statistical analyses 
Data for each of the serum lipid, apo, PS, lathosterol, PAI-1, leptin, hematological/metabolic, and 
anthropometric parameters were analyzed using paired t-tests to assess the differences from the 
baseline. Correlation coefficients were assessed using Pearson’s correlation test. A type I error rate of 
< 0.05 was considered to be statistically significant. The parameters measured in the nutrition test, 
blood test, and physical examinations were expressed as the mean ± standard deviation (SD).  
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2.3  Results 
 
Subjects and profile 
Subjects were comprised of 71 healthy adult volunteers (23 - 58 years). Based on the guideline of 
Japan Atherosclerosis Society for hyperlipidemias in adults (JAS, 1997), all subjects were 
categorized and evaluated (Table 2-1). The characteristics of subjects, according to their baseline 
levels of serum total cholesterol, are presented in Table 2-2. The subjects are equally divided into 
three groups (normal: < 5.17 mmol/L, 35 %; borderline: 5.17 - 5.68 mmol/L, 28 %; high: ≥ 5.69 
mmol/L, 37 %). 
 
Diet survey 
Total energy, fat, cholesterol, and experimental cooking oil intakes and the n-6/n-3 ratios are presented 
in Table 2-3. No remarkable changes were observed in any of the groups with respect to total energy 
and fat intake levels or n-6 / n-3 ratios from the test period to the wash-out period. In addition, there 
were no significant changes in experimental PS/DAG cooking oil intake levels, which was stable at 
15-17 g/day during the study. PS/DAG cooking oil was ingested on average at a rate of 16.3 g/day 
(total PS consumption: 680 mg/day) in all subjects and 16.0 g/day (total PS consumption: 667mg/d) 
in the high group. No adverse events were observed throughout the study. Cholesterol intake slightly 
increased from baseline during the test period in all subjects. However, this increase did not reach 
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statistical significance between groups despite a significantly higher cholesterol intake in the high 
group. No remarkable changes were observed (data not shown) with respect to other nutritional 
parameters such as protein, carbohydrate, and dietary fiber intake. The percentage of energy derived 
from fat was approximately 31.4%, which was somewhat higher than Japanese average (26.3%). 
Dietary record showed that subjects were more likely to have fatty foods. No subjects withdrew their 
consent due to the test oil. 
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Table 2-1  Diagnosis of blood lipids levels in Japanese adults 
Parameters (Unit) Low Normal  Borderline High 
Triacylglycerol (mmol/L) - < 1.69 - ≥ 1.69 
 (mg/dL) - < 150 - ≥ 150 
Total cholesterol (mmol/L) - < 5.17 5.17-5.68 ≥ 5.69 
 (mg/dL) - < 200 200-219 ≥ 220 
LDL cholesterol (mmol/L) - < 3.10 3.10-3.61 ≥ 3.62 
 (mg/dL) - < 120 120-139 ≥ 140 
HDL cholesterol (mmol/L) < 1.03 ≥ 1.03 - - 
 (mg/dL) < 40 ≥ 40 - - 
 
  
 29 
 
 
 
 
 
 
 
 
 
Table 2-2  Characteristics of subjects according to the baseline levels of serum TC 1 
 All subjects Normal  Borderline High 
Age (years) 41.1 ± 9.1 41.4 ± 9.3 39.5 ± 8.0 42.1 ± 9.9 
n (male / female) 71 (66 / 5) 25 (24 / 1) 20 (17 / 3) 26 (25 / 1) 
Body weight (kg) 66.9 ± 7.8 65.0 ± 7.3 65.0 ± 7.2 70.2 ± 7.9 
BMI (kg/m2) 23.3 ± 2.3 22.6 ± 1.7 22.7 ± 2.0 24.4 ± 2.5 
Total cholesterol (mmol/L) 5.40 ± 0.75 4.63 ± 0.44 5.35 ± 0.13 6.15 ± 0.44 
LDL cholesterol (mmol/L) 3.34 ± 0.59 2.82 ± 0.41 3.36 ± 0.28 3.85 ± 0.49 
HDL cholesterol (mmol/L) 1.37 ± 0.31 1.32 ± 0.34 1.45 ± 0.26 1.37 ± 0.31 
Triacylglycerol (mmol/L) 1.50 ± 1.08 1.12 ± 0.71 1.15 ± 0.43 2.13 ± 1.40 
1 Values are means ± SD. TC: total cholesterol. Normal, serum TC < 5.17 mmol/L; borderline, serum TC 
5.17-5.68 mmol/L; high, serum TC ≥ 5.69 mmol/L.  
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Table 2- 3  Dietary composition thoughout the test periods 1 
 
Study 
months 
All subjects  
(n = 71) 
 Normal 
(n = 25) 
 Borderline 
(n = 20) 
 High  
(n = 26) 
Energy  0 9255 ± 1552  9213 ± 1657  9368 ± 1418  9209 ± 1607 
（kJ/day） 1 9259 ± 1607  9364 ± 1707  9163 ± 1397  9230 ± 1707 
 3 9029 ± 1615  8979 ± 1761  9100 ± 1205  9021 ± 1791 
 6 9196 ± 1611  9297 ± 1770  9129 ± 1351  9146 ± 1695 
 +1 9268 ± 1749  8954 ± 1971  9795 ± 1644  9163 ± 1573 
Fat  0 75.4 ± 18.8  77.6 ± 18.1  77.3 ± 15.0  71.8 ± 21.9 
(g/day) 1 75.8 ± 20.5  75.7 ± 20.0  79.9 ± 22.9  72.8 ± 19.4 
 3 77.0 ± 18.0  79.2 ± 18.9  79.3 ± 15.7  73.3 ± 18.6 
 6 76.1 ± 18.0  79.5 ± 17.1  74.1 ± 15.3  74.3 ± 20.8 
 +1 77.2 ± 20.7  72.9 ± 19.2  87.9 ± 26.3  73.1 ± 14.0 
Cholesterol  0 396 ± 139  400 ± 162  439 ± 129  360 ± 116 
（mg/day） 1 411 ± 140  382 ± 118  440 ± 178   416 ± 127* 
 3 431 ± 144  427 ± 161  465 ± 159   409 ± 111* 
 6 429 ± 146  429 ± 134  408 ± 175   445 ± 135* 
 +1 434 ± 157  357 ± 126  502 ± 179    454 ± 140** 
n-6 / n-3  0 4.4 ± 1.7  4.9 ± 1.9  3.9 ± 1.2  4.3 ± 1.6 
(ratio/day) 1 4.7 ± 1.9  5.1 ± 1.8  4.9 ± 2.1  4.1 ± 1.6 
 3 4.0 ± 1.5    3.9 ± 1.4**  4.5 ± 1.7  3.7 ± 1.4 
 6 4.6 ± 1.9  4.7 ± 1.7  4.6 ± 1.8  4.6 ± 2.2 
 +1 4.5 ± 1.7  4.6 ± 1.6  4.7 ± 1.7  4.1 ± 2.0 
Test oil  0 15.6 ± 7.4  15.4 ± 6.9  16.9 ± 7.9  14.7 ± 7.7 
(g/day) 1 16.9 ± 7.3  15.9 ± 6.9  18.1 ± 7.7  16.9 ± 7.6 
 3 16.8 ± 7.4  16.2 ± 8.6  18.1 ± 6.4  16.4 ± 7.0 
 6 15.1 ± 6.5  15.8 ± 5.5  14.9 ± 7.9  14.6 ± 6.5 
 +1 16.9 ± 7.8  16.7 ± 7.9  20.5 ± 8.7  14.5 ± 6.2 
1 Values are means ± SD. Significantly different from baseline (= 0week) determined by Student’s t-test : *P < 
0.05. **P < 0.01. TC: total cholesterol. Normal, serum TC < 5.17 mmol/L; borderline, serum TC 5.17-5.68 
mmol/L; high, serum TC ≥ 5.69 mmol/L. 
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Blood lipids and apos analyse 
At first, the subjects were divided into 2 to 3 groups according to baseline values of each serum lipid 
concentration, and each group was evaluated separately (Fig. 2-2). During the run-in period (-1 
month to the beginning of the test period) when all subjects consumed conventional TAG cooking oil, 
no significant changes in total cholesterol, LDL cholesterol, HDL cholesterol, and triacylglycerol 
concentrations were observed.  
Next, Table 2-4 presents details about the effects of the experimental oil on serum lipids in 
the three groups of subjects that were categorized based on their serum total cholesterol baseline 
concentrations. No significant changes in total cholesterol, LDL cholesterol, HDL cholesterol, and 
triacylglycerol concentrations or LDL cholesterol / HDL cholesterol ratios were observed in any of 
the study groups during the control period (-1 month to the beginning of the test period) when 
subjects consumed conventional TAG cooking oil (data not shown). Significant decreases in total 
cholesterol and LDL cholesterol were observed at 1 and 3 months for all subjects. In the high group, 
total cholesterol and LDL cholesterol concentrations decreased significantly from baseline values by 
7.1% (P < 0.001) and 8.1% (P < 0.01) at 1-month, respectively. Subjects in the high group 
experienced a cholesterol-lowering effect of the experimental oil on total cholesterol and LDL 
cholesterol concentrations at 1-month in 81% and 73%, respectively. The statistically significant 
difference from baseline cholesterol concentration persisted until the end of the 6-month period and 
was still present during the final wash-out period. Although statistically not significant, total 
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cholesterol and LDL cholesterol concentrations in the borderline group also decreased up to the end 
of the 6-month period. Neither the total cholesterol nor LDL cholesterol concentrations showed an 
apparent change in the normal group. HDL cholesterol concentrations tended to increase gradually 
following continued use of the experimental cooking oil even though significant decreases were 
observed in all groups except the high group at 1 month. HDL cholesterol concentrations at 6 months 
significantly increased for all subjects combined and those in the normal group by 3.8% (P < 0.01) 
and 3.9% (P < 0.05), respectively. LDL cholesterol / HDL cholesterol ratios in all subjects 
significantly decreased by 6.5% (P < 0.001) by the end of the 6-month period. This effect was 
especially evident in the high group where the ratios decreased by 6.3 - 9.3% during the test period. 
HDL cholesterol concentrations and LDL cholesterol / HDL cholesterol ratios after the wash-out 
period were not significantly different from those observed at baseline. RLP-C and triacylglycerol 
concentrations particularly decreased in the high group, however the differences from baseline did 
not reach statistical significance. On the other hand, changes in triacylglycerol concentrations were 
strongly correlated with changes in RLP-C concentrations (R = 0.839, P < 0.001), as shown in Fig. 
2-3. In addition, there is a negative correlation between changes in serum triacylglycerol 
concentrations and HDL cholesterol concentrations ( R = 0.430, P < 0.001). 
 Table 2-5 shows changes in the apos that were measured from the baseline test period to 
+1 month after the wash-out period. ApoAI concentrations in each group except the borderline group 
at 3 months, significantly increased by an average of 4-5% (P < 0.05) by the end of 6 months. This 
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statistically significant increase in apoAI concentrations was maintained in all subjects even after the 
wash-out period. ApoB concentrations in all subjects significantly decreased by 4.6% (P < 0.001) and 
5.6% (P < 0.001) at the 3- and 6-month points, respectively. This effect was particularly evident in the 
high group where a 6.3% decrease was observed. The apoB / apoAI ratios in each group significantly 
decreased by an average of 8-10% (P < 0.001) at the end of 6 months. There were no significant 
differences from the baseline concentrations of apoB and apoB / apoAI ratios after the wash-out 
period. Although no significant changes in apoCII were observed in any groups during the PS/DAG 
treatment period, the level significantly increased after the washout period in the normal group and in 
all subjects.  
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Anthropometry related parameters analyses 
In the present study, an average value of BMI was the almost same as Japanese national average 
(male: 23.1; female: 22.5), and normal size. No remarkable changes in BMI or weight were observed 
during the test period (Table 2-6). However, at 6 months, subcutaneous fat thickness and serum 
leptin concentrations in male subjects significantly reduced by 3.2% (P < 0.05) and 6.9% (P < 0.05), 
respectively. Changes in serum leptin concentrations were weakly correlated with changes in 
subcutaneous fat thickness (R = 0.284, P = 0.021). In addition, plasma PAI-1 concentration for 
subjects with a baseline concentration > 30 ng/mL (n = 10) was significantly reduced from baseline 
by 37.5% at the end of 1 month (P < 0.001) and this reduction was maintained until the end of the 
6-month period. 
 
Other blood parameters analyses 
Serum β-sitosterol and campesterol concentrations in each group significantly increased by an 
average of 21-27% and 35-45%, respectively, by the end of 6 months (Table 2-7). After the wash-out 
period (+1 month), β-sitosterol and campesterol concentrations in each group returned to near 
baseline concentrations. Lathosterol did not increase by the end of the 6-month period. Changes in 
serum total cholesterol concentrations were moderately correlated with baseline values (0 month) in 
β-sitosterol concentrations (a cholesterol absorption marker) (R = 0.308, P < 0.05) (Tilvis & 
Miettinen, 1986), and also mildly correlated with baseline values (0 month) in lathosterol 
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concentrations (a cholesterol synthesis marker) (R = 0.204, P = 0.100) (Miettinen et al., 1990). 
No significant changes in white blood cell (WBC), haemoglobin, NEFA, GPT, or γ-GTP 
were observed in any subjects. Red blood cell (RBC), hematocrit (in the high group only), PL, and 
AST changed significantly in all subjects; however, levels for each of these parameters remained 
within their normal ranges (Table 2-8).  
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Fig. 2-2  Effects of dietary PS/DAG oil consumption on serum cholesterols concentrations（n=71） 
Values are means ± SE, Significant difference from baseline: * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Table 2-4  Effects of PS/DAG oil on serum lipids by group classified by baseline TC 1 
 
Parameters 
Study 
months 
All subjects 
(n=71) 
Normal 
(n=25) 
Boderline 
(n=20) 
High 
(n=26) 
Total  -1 5.40 ± 0.78  4.63 ± 0.52  5.46 ± 0.44  6.08 ± 0.47  
cholesterol 0 5.40 ± 0.75  4.63 ± 0.44  5.35 ± 0.13  6.15 ± 0.44  
(mmol/L) 1 5.15 ± 0.70 *** -4.8% 4.55 ± 0.54 -1.7% 5.17 ± 0.34 -3.4% 5.72 ± 0.57 *** -7.1% 
 3 5.25 ± 0.70 ** -2.9% 4.68 ± 0.52 1.1% 5.20 ± 0.47 -2.9% 5.84 ± 0.47 *** -5.0% 
 6 5.33 ± 0.70 -1.4% 4.76 ± 0.49 2.8% 5.30 ± 0.34 -1.0% 5.87 ± 0.59 ** -4.6% 
 +1 5.38 ± 0.75 -0.5% 4.71 ± 0.47 1.7% 5.43 ± 0.52 1.4% 5.95 ± 0.59 * -3.4% 
LDL  -1 3.31 ± 0.672  2.79 ± 0.49  3.44 ± 0.54  3.75 ± 0.54  
cholesterol 0 3.34 ± 0.59  2.82 ± 0.41  3.36 ± 0.28  3.85 ± 0.49  
(mmol/L) 1 3.21 ± 0.62 ** -3.9% 2.82 ± 0.54 0.0% 3.28 ± 0.39 -2.3% 3.54 ± 0.65 ** -8.1% 
 3 3.21 ± 0.57 ** -3.9% 2.82 ± 0.47 0.0% 3.23 ± 0.47 -3.8% 3.57 ± 0.49 ** -7.4% 
 6 3.26 ± 0.59 -2.3% 2.87 ± 0.47 1.8% 3.31 ± 0.39 -1.5% 3.62 ± 0.57 ** -6.0% 
 +1 3.31 ± 0.595 -0.8% 2.87 ± 0.47 1.8% 3.41 ± 0.54 1.5% 3.62 ± 0.52 ** -6.0% 
HDL  -1 1.34 ± 0.31  1.27 ± 0.28  1.45 ± 0.28  1.37 ± 0.31  
cholesterol 0 1.37 ± 0.31  1.32 ± 0.34  1.45 ± 0.26  1.37 ± 0.31  
(mmol/L) 1 1.32 ± 0.28 *** -3.8% 1.24 ± 0.26 * -5.9% 1.37 ± 0.28 ** -5.4% 1.34 ± 0.28 -1.9% 
 3 1.37 ± 0.31 0.0% 1.34 ± 0.34 2.0% 1.42 ± 0.26 -1.8% 1.37 ± 0.34 0.0% 
 6 1.42 ± 0.31** 3.8% 1.37 ± 0.31 * 3.9% 1.53 ± 0.31 5.4% 1.42 ± 0.34 3.8% 
 +1 1.37 ± 0.31 0.0% 1.32 ± 0.28 0.0% 1.45 ± 0.28 0.0% 1.34 ± 0.31 -1.9% 
LDL  -1 2.58 ± 0.78  2.33 ± 0.77  2.49 ± 0.73  2.88 ± 0.75  
cholesterol 0 2.57 ± 0.76  2.29 ± 0.73  2.42 ± 0.67  2.96 ± 0.72  
/ HDL 1 2.55 ± 0.75 -0.8% 2.37 ± 0.74 3.2% 2.50 ± 0.72 3.2% 2.77 ± 0.77 * -6.3% 
cholesterol 3 2.46 ± 0.72 ** -4.3% 2.23 ± 0.69 -3.0% 2.3 9 ± 0.66 -1.3% 2.74 ± 0.72 ** -7.3% 
 6 2.41 ± 0.74 *** -6.5% 2.20 ± 0.71 -4.0% 2.30 ± 0.74 * -5.1% 2.68 ± 0.71 *** -9.3% 
 +1 2.56 ± 0.81 -0.4% 2.32 ± 0.73 1.1% 2.49 ± 0.89 2.9% 2.85 ± 0.77 -3.6% 
Triacylglycerol -1 1.61 ± 1.02  1.28 ± 0.81  1.26 ± 0.67  2.21 ± 1.16  
(mmol/L) 0 1.50 ± 1.08  1.12 ± 0.71  1.15 ± 0.43  2.13 ± 1.40  
 1 1.42 ± 0.98 -5.3% 1.15 ± 0.96 3.0% 1.11 ± 0.49 -3.9% 1.94 ± 1.11 -9.0% 
 3 1.47 ± 1.08 -2.3% 1.13 ± 0.86 1.0% 1.19 ± 0.54 2.9% 2.02 ± 1.37 -5.3% 
 6 1.35 ± 0.87 -9.8% 1.10 ± 0.75 -2.0% 1.04 ± 0.49 -9.8% 1.84 ± 1.02 -13.8% 
 +1 1.58 ± 1.16 5.3% 1.19 ± 0.72 6.1% 1.20 ± 0.52 3.9% 2.25 ± 1.52 5.3% 
RLP  0 6.1 ± 5.1  4.1 ± 2.7  4.6 ± 1.4  9.2 ± 6.9  
cholesterol 3 6.1 ± 4.9 0.0% 4.3 ± 3.1 4.9% 5.0 ± 2.2 8.7% 8.7 ± 6.7 -5.4% 
(mg/dL) 6 5.3 ± 3.6 -13.1% 4.2 ± 2.7 2.4% 4.4 ± 2.0 -4.3% 7.1 ± 4.5 -22.8% 
 +1 6.9 ± 6.2 13.1% 4.8 ± 2.7 17.1% 5.4 ± 3.0 17.4% 10.0 ± 8.9 8.7% 
1 Mean ± SD. Significantly different from baseline (= 0week) determined by Student’s t-test: *P < 0.05. **P < 0.01, ***P < 0.001. TC: total 
cholesterol. Normal, serum TC < 5.17 mmol/L; borderline, serum TC 5.17-5.68 mmol/L; high, serum TC ≥ 5.69 mmol/L. 
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Table 2-5  Effects of PS/DAG oil on serum apos by group classified by baseline TC 1 
Parameters Study 
months 
All subjects 
 (n=71) 
Normal 
 (n=25) 
Boderline 
(n=20) 
High 
(n=26) 
ApoAI  0 141 ± 21  134 ± 24  145 ± 18  145 ± 21  
(mg/dL) 3 146 ± 21*** 3.5% 141 ± 22 *** 5.2% 147 ± 17 1.4% 149 ± 24 * 2.8% 
 6 147 ± 21*** 4.3% 139 ± 19 * 3.7% 152 ± 20 * 4.8% 151 ± 21 * 4.1% 
 +1 145 ± 20* 2.8% 139 ± 21 3.7% 148 ± 20 2.1% 148 ± 19 2.1% 
ApoB  0 108 ± 22  91 ± 17  103 ± 12  127 ± 18  
(mg/dL) 3 103 ± 20*** -4.6% 89 ± 16 -2.2% 99 ± 15 -3.9% 119 ± 16 *** -6.3% 
 6 102 ± 22*** -5.6% 88 ± 17 -3.3% 99 ± 12 * -3.9% 119 ± 21 *** -6.3% 
 +1 109 ± 24 0.9% 93 ± 19 2.2% 106 ± 16 2.9% 126 ± 22 -0.8% 
ApoB / ApoA I  0 0.78 ± 0.21  0.70 ± 0.20  0.73 ± 0.18  0.90 ± 0.19  
 3 0.72 ± 0.18 *** -7.5% 0.65 ± 0.17 ** -6.8% 0.69 ± 0.15 * -5.9% 0.82 ± 0.18 *** -9.1% 
 6 0.71 ± 0.19 *** -9.1% 0.65 ± 0.17 *** -7.6% 0.67 ± 0.17 *** -8.9% 0.81 ± 0.19 *** -10.3% 
 +1 0.77 ± 0.22 -1.7% 0.69 ± 0.20 -1.3% 0.74 ± 0.20 0.3% 0.87 ± 0.21 -3.1% 
1 Mean ± SD. Significantly different from baseline (= 0 week) determined by Student’s t-test: *P < 0.05. **P < 0.01, 
***P < 0.001. TC: total cholesterol. Normal, serum TC < 5.17 mmol/L; borderline, serum TC 5.17-5.68 mmol/L; high, 
serum TC ≥ 5.69 mmol/L.  
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Table 2-6  Effects of PS/DAG oil on anthropometrics parameters, serum leptin and plasma PAI-1 1 
 
Parameters 
Study 
months 
All subjects  
(n=71) 
Changes 
BMI (kg/m2) -1  23.3 ± 2.3 - 
 (All subjects, n = 71) 0  23.3 ± 2.3 - 
 1  23.3 ± 2.3 -0.1% 
 3  23.4 ± 2.3  0.3% 
 6  23.4 ± 2.3  0.5% 
 +1  23.5 ± 2.3**  0.9% 
Subcutaneous fat -1  27.4 ± 9.6 - 
thickness (mm) 0  28.0 ± 9.7 - 
(Male subjects, n = 66) 1  27.5 ± 9.5 -1.7% 
 3  27.3 ± 9.7 -2.4% 
 6  27.1 ± 9.6* -3.2% 
 +1  27.5 ± 9.5 -1.7% 
Leptin (ng/mL) 0   4.3 ± 2.3 - 
(Male subjects, n = 66) 6   4.0 ± 2.2* -6.9% 
 +1   4.3 ± 2.2  1.4% 
PAI-1 (ng/mL) -1  45.6 ± 25.1 - 
(High levels, n = 10) 2 0  46.1 ± 11.6 - 
 1  28.8 ± 10.1*** -37.5% 
 3  37.3 ± 16.9 -19.1% 
 6  33.3 ± 13.3** -27.8% 
 +1  39.4 ± 15.4 -14.5% 
1 Values are means ± SD. Significantly different from baseline (= 0week) determined by Student’s t-test: *P < 
0.05. **P < 0.01, ***P < 0.001. 2 Subjects with the high level of baseline (PAI-1 > 30 ng/mL). 
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Table 2-8  Changes in hematological and other serum indices 1 
 Study 
months 
All subjects 
(n = 71) 
Normal 
 (n = 25) 
Borderline 
(n = 20) 
High 
(n = 26) 
Hematology 
RBC (104/μL) 0 489 ± 40 488 ± 29 470 ± 49 506 ± 34 
 6 494 ± 38 * 496 ± 26 * 478 ± 49 * 505 ± 35 
WBC (/μL) 0 6006 ± 1700 6020 ± 1589 5700 ± 2109 6227 ± 1470 
 6 5742 ± 1703 5728 ± 1496 5150 ± 1484 6212 ± 1947 
HB (g/dL) 0 14.9 ± 1.2 14.9 ± 0.8 14.3 ± 1.6 15.4 ± 0.9 
 6 15.0 ± 1.2 15.0 ± 0.7 14.7 ± 1.6 15.4 ± 1.1 
HT (%) 0 45.3 ± 3.4 44.8 ± 2.3 43.9 ± 4.4 46.8 ± 2.8 
 6 45.0 ± 3.1 45.0 ± 2.2 43.9 ± 4.0 45.8 ± 3.0 * 
Others 
NEFA (μEq/L) 0 507 ± 209 462 ± 163 470 ± 203 579 ± 238 
 6 526 ± 235 471 ± 224 601 ± 235 * 523 ± 238 
PL (mmol/L) 0 3.11 ± 0.48 2.75 ± 0.31 3.06 ± 0.18 3.51 ± 0.47 
 6 3.01 ± 0.39 ** 2.73 ± 0.26 2.97 ± 0.23 3.32 ± 0.37 * 
AST (IU/L) 0 22 ± 8 21 ± 6 22 ± 12 23 ± 7 
 6 24 ± 13 * 22 ± 7 25 ± 17 26 ± 15 
ALT (IU/L) 0 27 ± 18 25 ± 17 23 ± 15 33 ± 19 
 6 30 ± 21 25 ± 16 26 ± 21 37 ± 23 
γ-GPT (IU/L) 0 51 ± 42 45 ± 50 36 ± 25 68 ± 38 
 6 57 ± 57 46 ± 60 41 ± 37 79 ± 61 
1 Values are means ± SD. Significantly different from baseline (= 0 week) determined by Student’s t-test: *P < 
0.05. TC: total cholesterol. Normal, serum TC < 5.17 mmol/L; borderline, serum TC 5.17-5.68 mmol/L; high, 
serum TC ≥ 5.69 mmol/L. 
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2.4  Discussion 
 
The present study investigated the long-term effects of PS in combination with DAG oil on levels of 
serum lipids, apos and anthropometric parameters among healthy adults. The subjects substituted 
their normal cooking oil with PS/DAG oil during the test period after a specified control period. 
In the previous controlled studies of DAG oil, the cholesterol-lowering effect has not 
directly shown in DAG oil group similar to TAG oil group (Nagao et al., 2000; Maki et al., 2002; 
Yamamoto et al. 2001). Thus, with addition of PS to DAG oil, the serum total cholesterol and LDL 
cholesterol lowering effect was expected to become clearly evident. In addition, it has been reported 
that PS is more soluble in DAG oil (6.0%) than it is in TAG oil (1.3%) (Meguro et al., 2001), and the 
low daily ingestion of 400-500 mg of PS dissolved in DAG oil achieved a cholesterol-lowering 
effect (Goto et al., 1999; Meguro et al., 2001; Saito et al., 2006a).  
In the present study, significant reductions in serum total and LDL cholesterols 
concentrations were also shown in the high group at 1-month of PS/DAG oil consumption and 
maintained to the end of the 6-month period, even though the average intake of PS (667 mg/day) in 
high group was lower than those of previous human studies with PS esters dissolved in TAG oil (PS 
740 and 830 mg/day) (Pelletier et al., 1995; Hendriks et al., 1999). Moreover, the 
cholesterol-lowering effect by PS was clearly shown in the subjects with increased cholesterol 
absorption in the small intestine (high level of β-sitosterol in serum) rather than those with increased 
cholesterolgenesis in the liver (high level of lathosterol in serum). Those results indicate that the 
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inhibition of dietary cholesterol absorption is basically effective for the management of cholesterol in 
general. 
Recent report has revealed that a soy lecitihin formulation remarkably elevated the 
solubility of β-sitostanol in bile acid micelles and significantly reduced cholesterol adsorption at 
lower doses (300 and 700 mg) (Ostlund et al., 1999). Thus, DAG might be expected to be one of the 
effective solvents such as lecithin, could facilitate to dissolve high levels of PS in the bile acid 
micelles of the intestine and that those micelles could significantly reduce cholesterol absorption in 
the small intestine at lower doses. 
The cholesterol-lowering effects gradually appeared to decline with time (Table 2-4). This 
effect might be attributed to an increase of dietary cholesterol intake levels obtained from special 
meals and a decrease of the frequency of test oil ingestion, because the later stages of study 
overlapped with a celebratory season (December and January) when subjects were more likely to 
dine out and eat nourishing meals (Table 2-3). On the other hand, serum lathosterol concentrations 
did not remarkably change during the test period (Table 2-7). These findings suggest that a gradual 
decline in the cholesterol-lowering effect in this study can be attributed to elevated consumption of 
dietary cholesterol rather than the activation of cholesterol synthesis in the liver. 
DAG oil composed mainly of 1,3-species has been shown to suppress the post-prandial 
elevation of serum triacylglycerol concentrations and decrease serum fasting triacylglycerol 
concentrations (Yamamoto et al., 2001). The triacylglycerol resynthesis in small intestinal epithelial 
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cells may be delayed after the ingestion of DAG (mainly 1,3-species of DAG) (Hara et al., 1993; 
Murata et al., 1994; Taguchi et al., 2000; Tada et al., 2001; Tada et al., 2005). In this study, the serum 
triacylglycerol concentration tended to greatly decrease at the end of 6-month test period, although 
not significant. Thus, the decrease in triacylglycerol concentrations in this study can also be attributed 
to the ingestion of DAG oil rather than PS as has previously been reported (Yamamoto et al., 2001). 
Moreover, the decrease in triacylglycerol concentrations by DAG oil contributed to increases in HDL 
cholesterol concentration (Fig. 2-3), since it has not been shown that PS change HDL cholesterol 
concentration so far (Jones et al., 1997). This effect suggests that DAG oil may be effective in 
preventing arteriosclerosis and thrombosis. 
It was especially showed that various parameters related with HDL cholesterol, LDL 
cholesterol, and remnant particles in serum such as apoAI and B were significantly improved in all 
subject groups with PS/DAG oil.  
DAG oil has reduced the abdominal fat in humans (Nagao et al., 2000; Maki et al., 2002). 
In studies with animals, DAG oil was suggested to have a higher capacity for hepatic lipid oxidation 
and a decrease in leptin levels (Murata et al., 1997; Murase et al., 2001). In this study, PS/DAG oil 
did not affect the body weights of the subjects within the normal range for BMI, however 
subcutaneous fat thickness and serum leptin concentrations, which are known to correlate closely 
with obesity (Considine et al., 1996), significantly decreased by 3.2% and 6.9% by the end of a 
6-month consumption period in male subjects (n = 66). Further, plasma PAI-1 concentrations, which 
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are known to correlate with visceral fat mass (Shimomura et al., 1996), also decreased in subjects 
who had high baseline PAI-1 concentrations. These combined results suggest that the long-term use 
of PS/DAG oil as cooking oil could contribute to the prevention of or reduction in central obesity by 
DAG oil, in addition to cholesterol-lowering effects of PS.  
In healthy humans, the absorption rate of β-sitosterol in the small intestine was reported 
modest 5.0% (Kritchevsky, 1997). However, high levels of PS in serum might become a risk of 
arteriosclerosis, because in phytosterolemia, an extremely rare inherited disease, high levels of PS in 
the blood vessels induce arteriosclerosisis (Salen et al., 1992). In this study, serum PS concentrations 
were within the 1% of serum total cholesterol concentration and quickly returned to those of baseline 
after a 1-month wash-out period (Table 2-7). This observation indicates that PS solubilized in DAG 
oil were normally absorbed in the small intestine, were immediately eliminated through billiary 
secretion and did not accumulate in the body similar to PS in TAG oil. Furthermore, the rates of those 
levels, although increased, were remarkably lower compared to a previous report that showed a 70% 
increment with a difference in doses of PS (Weststrate & Meijer, 1998). On the other hand, no 
significant change in serum lathosterol concentrations was observed. It is concluded that a low intake 
of PS in the present study can’t induce the cholesterol synthesis in the liver, resulting from the 
feedback effect of PS. Changes in hematological results and serum chemistry fell within normal 
ranges and were not statistically significant (Table 2-8) suggesting that PS/DAG oil ingestion has a 
safe profile in humans. 
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In conclusion, western diets have involved with increases in the risk factors associated with 
arteriosclerosis. In the present study, PS/DAG oil consumption play a role to ameliorate blood 
concentrations of total and LDL cholesterols, HDL cholesterol, triacylglycerol, remnant, PAI-1, and 
body fat parameters without adverse effects. This indicates that PS/DAG oil could be beneficial in 
the primary prevention of arteriosclerosis and obesity if used daily in place of conventional cooking 
oils.  
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CHAPTER 3 
 
Potential impact of dietary phytosterol-rich diacylglycerol oil on 
atherogenic lipoproteins in postmenopausal women 
 
3.1  Introduction 
 
Estrogen has a protective effect against atherosclerosis due to a decreased blood concentration of “bad” 
low-density lipoprotein (LDL) cholesterol and increased “good” high-density lipoprotein (HDL) 
cholesterol. Because of estrogen depletion, the onset of menopause dramatically increases atherogenic 
blood lipoprotein concentrations, especially LDL and lipoprotein (a) [Lp(a)], resulting in a precipitous 
climb in CVD rates (Jenner et al., 1993; Davidson et al., 2002; Welty, 2004;Thom et al., 2006). 
Large-scale clinical trials indicate that lowering cholesterol is beneficial for preventing morbidity and 
death associated with CVD, irrespective of sex (Sacks et al., 1996; Downs et al., 1998; Heart 
Protection Study Collaborative Group, 2002; Athyros et al., 2002). As a first-line therapy for the 
management of cholesterol in postmenopausal women, diet and other lifestyle changes are 
recommended (Expert panel on detection, evaluation, and treatment of high blood cholesterol in 
adults, 2001). 
 Chapter 2 showed that the 6-month ad libitum consumption of PS/DAG cooking oil 
substantially and reduces blood total and LDL cholesterol concentrations in almost male subjects with 
moderate to hypercholesterolemia without dietary restriction (Takeshita et al, 2001). In this chapter, it 
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is demonstrated that a month consumption of PS/DAG cooking oil further reduces elevated 
atherogenic blood LDL cholesterol and Lp(a) concentrations in postmenopausal women with 
elevated blood cholesterol concentrations, compared to DAG oil. These findings suggest that 
PS/DAG oil has potential benefits for reducing risk factors for CVD, even in women with age-related 
hypercholesterolemia. 
 
 
3.2  Materials and methods 
 
Study design 
The study was a randomized, double-blind, controlled study, performed in a crossover manner 
comprising two 4-week intervention periods (Fig. 3-1). The study was performed under the 
supervision of an occupational health physician, in accordance with the regulations of the Kao 
Corporation Ethics Committee for Internal Clinical Studies and in conformity with the Helsinki 
Declaration. The conditions and procedures used in this study were reviewed with all subjects 
previous to obtaining their written informed consent. 
 
Subjects 
Twenty-five healthy female employees of the Kao Corporation who were 45-year-old and over were 
recruited for the study. Eleven individuals were not eligible to participate at that moment because they 
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were judged as pre-menopausal or whose serum total cholesterol concentrations were less than 5.17 
mmol/L (200 mg/dL). In Japan, the recommended total cholesterol goal for postmenopausal women 
for the primary prevention of CVD is less than 200 mg/dL (5.17 mM) and dietary therapy is advised 
for postmenopausal women whose levels are above the borderline (JAS, 1997). Fourteen subjects 
after spontaneous menopause, who were more than a year away from menopause, were enrolled in 
the study. All the subjects were healthy and were taking no medication for blood glucose levels, lipid 
levels, blood pressure, or hormone replacement therapy.  
 
Experimental methods 
All subjects were randomly assigned to one of two groups and each group consumed either PS/DAG 
oil or DAG oil for a period of 4 weeks. The subjects were then given a four-week “wash-out period” 
before crossing over and receiving the other oil for an additional 4 weeks. The test oils were labelled 
with a blind code and were consumed as a replacement for the edible oils. The oils were used mainly 
as a cooking (fried, deep-fried) and were also used partly in the domestic use of handmade dressings 
such as salad dressing and mayonnaise, and curry at each subject’s home. The target dose of the test 
oils was 10 g/day, equivalent to the average intake of an edible oil in Japan (JMHLW, 2002). The 
subjects were instructed to maintain their usual daily isocaloric diets, nonessential groceries (coffee 
and tobacco) and physical activities, and to limit their alcohol consumption no more than 30 g/day 
during the study period. In addition, the subjects were instructed to abstain from alcohol for 2 days 
 50 
 
 
prior to each blood sampling and to fast for 12 hours before the blood sampling which was 
conducted in the morning at 4 week intervals. The physicians checked the health conditions of the 
subjects at every blood sampling and gave advice. The subjects were instructed to keep a dietary 
record for a three-consecutive-day before the blood sampling and to submit it at each visit.  The 
mean daily intake of total energy, fat, fiber, cholesterol, and test oil were calculated by a dietician 
from the dietary record based on the 4th revised Japanese Food Composition Table (JST, 1998) . In 
addition, the actual frequency, application (fried, deep-fried, dressings and the others) and 
consumption of test oils at home was verified by a questionnaire survey throughout the period of the 
test oil treatments. 
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Fig. 3-1  Diagram of the study design 
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Test oils 
The test oils used in the study were functional cooking oils manufactured in Japan and permitted as 
FOSHU Use by The Ministry of Health, Labour and Welfare of Japan. DAG oil (Econa Cooking Oil 
®, Kao Corporation, Tokyo Japan) contained ~80 g DAG / 100 g and the major fatty acids of this oil 
were linoleic and oleic acids (Table 3-1). PS/DAG oil (Econa H&H Cooking Oil ®, Kao Corporation, 
Tokyo Japan) was prepared from DAG oil and PS diluted from soy bean and rapeseed oils. The 
PS/DAG oil contained 4.20 g of free forms of PS in 100 g, while the DAG oil contained 0.28 mg of 
PS in 100 g (Table 3-2). The test oils were stable during cooking and very similar to conventional 
cooking oils (TAG oil) in taste, flavour and appearance and were indistinguishable from each other. In 
the United States, the Food and Drug Administration has listed DAG oil as a “Generally Recognized 
as Safe” substance. 
  
 53 
 
 
 
 
 
 
Table 3-1  Composition of acylglycerol and fatty acids in DAG oil 
 DAG oil 
Acylglycerol Species (wt%)  
 Triacylglycerol 15.8 
 1(or 3), 2-Diacylglycerol 28.8 
 1,3-Diacylglycerol 54.8 
 Monoacylglycerol 0.6 
Fatty acids composition (wt%)  
 C16:0 2.4 
 C18:0 0.7 
 C18:1 28.1 
 C18:2 61.2 
 C18:3 7.3 
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Table 3-2  Composition of plant sterols in DAG oil and PS/DAG oil  
 DAG oil PS/DAG oil 
β-Sitosterol (g) 0.16 1.86 
Stigmasterol (g) 0.05 1.22 
Campesterol (g) 0.06 1.01 
Brassicasterol (g) 0.01 0.11 
Total (g) 0.28 4.20 
(g/100 g oil) 
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Blood analyses 
Blood samples were collected from fasting subjects and serum was obtained by centrifugation at 1500 
×g for 15 minutes at 4°C, stored at 4°C or -80°C. All analyses except for noncholesterol sterols were 
conducted by SRL, Inc. (Tokyo, Japan). Serum total, LDL and HDL cholesterols and triacylglycerol 
concentrations were measured using an enzymatic assay. Serum apoAI and apoB concentrations were 
measured using a turbidimetric immunoassay. Serum AST, ALT and γ-GTP activities were measured 
using an enzymatic assay. Lp(a) concentrations were measured using an antihuman Lp(a) monoclonal 
antibody-coated latex assay. Serum total bile acid (TBA) concentrations were measured using an 
enzymatic assay kit (ENZABILE-Auto, Daiichi Pure Chemicals Co., Ltd.).  Estradiol concentrations 
were measured using a radioimmunoassay. Follicle-stimulating hormone activity was measured using 
a chemiluminescent enzyme immunoassay. Serum campesterol, β-sitosterol, and lathosterol 
concentrations were analyzed at the Kao Corporation by a Hewlett Packard (Agilent Technologies) 
5890A Gas chromatograph with the flame ionization detector with a DB-5HT column (15 m × 0.25 
mm, J&W Co., USA) using saponified serum extract as their trimethylsilyl derivatives. These sterols 
were quantified using 5α-cholestane as the internal standard (Gylling et al., 1999). The serum 
concentrations of noncholesterol sterols were standardized by the ratio to serum total cholesterol 
concentration and multiplied by 102 and are expressed as mmol/mol of cholesterol.  
 
Statistical analyses  
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A power calculation was performed to determine the required number of subjects. A sample size of 12 
subjects would have a power of 80% to detect a difference of ≈ 10 % in LDL cholesterol with α = 
0.05. Values are expressed as means ± SD. Statistical differences between the diet periods were tested 
with the use of the nonparametric Wilcoxon matched paired signed ranks test (two-tailed). The 
changes within the diet periods (start - end) were used for comparison of variables. The significant 
levels were set at P < 0.05 for all variables. Correlation coefficients were assessed using the 
Spearman’s rank test. No period or carryover effects were observed in this study. The statistical 
analyses were performed with SPSS version 11.0 (SPSS Inc., Chicago, IL). 
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3.3  Results 
 
Subjects and profile 
The baseline physical and blood profiles for the 14 subjects were as follows: age, 52.2 ± 5.0 years 
(45-62); height, 153.3 ± 5.4 cm (146-166); weight, 54.2 ± 8.8 kg (40-79); BMI, 23.0 ± 2.7 kg/m2 
(19-29); serum triacylglycerol, 1.13 ± 0.54 mmol/L (0.41-2.33); total cholesterol, 6.06 ± 0.75 mmol/L 
(5.15-7.47); LDL cholesterol, 3.69 ± 0.65 mmol/L (2.71-4.65); HDL cholesterol, 1.62 ± 0.37 mmol/L 
(0.93-2.59). No changes in body weight were found throughout the study (data not shown). 
 
Diet survey 
The mean total energy, fat, fiber, cholesterol and intake of the test cooking oil of all subjects at the start 
and end of the two diet periods are shown in Table 3-3. There were no significant differences in total 
energy, fat, fiber, and cholesterol intake between the two diet periods. During each period, the 
percentage of energy derived from fat was approximately 30% and the ratios of saturated-, 
mono-unsaturated-, and poly-unsaturated-fats were 1:1.1:0.8. The average intake of PS from the 
PS/DAG and control oils were 563 and 50 mg/day, respectively (P = 0.001). Three smokers (two 
subjects < 20 cigarettes/day; one subject ≥ 20 cigarettes/day) participated in the study, and tobacco 
consumption remained unchanged throughout the study. In addition, 12 subjects had coffee constantly, 
but not more than 3 cups per day in the study. 
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Table 3-3  Dietary intake of the subjects in the two diet periods 1 
 
 Control period 
(DAG oil) 
 Test period  
(PS/DAG oil) 
 
P 2 
  Start  End  Start  End  
Energy (MJ/day)  7.55 ± 1.98  7.56 ± 1.08  7.20 ±  1.17  7.23 ± 1.19  NS 
Fat (% of energy)  32.0 ± 9.7  31.9 ± 6.5  29.9 ± 7.2  30.6 ± 6.9  NS 
Saturated  11.4 ± 5.9  11.2 ± 2.5  11.6 ± 4.3  11.1 ± 4.0  NS 
Mono-unsaturated  12.5 ± 5.9  12.4 ± 2.5  11.2 ± 3.3  12.1 ± 4.3  NS 
Poly-unsaturated  8.2 ± 2.9  8.4 ± 2.4  7.0 ± 1.7  7.3 ± 2.0  NS 
Fiber (g/day)  17.0 ± 4.6  15.0 ± 3.1  15.1 ± 5.3  15.3 ± 4.8  NS 
Cholesterol (mg/day)  321 ± 113  360 ± 184  320 ± 125  361 ± 114  NS 
Test oil (g/day)  16.7 ± 6.1  17.8 ± 5.9  12.6 ± 5.1  13.4 ± 6.0  NS 
PS from test oil (mg/day)  47 ± 17  50 ± 16  35 ± 14   563 ± 250  0.001 
1 Values are means ± SD (n=14). 2 Difference between the changes in the two periods using the Wilcoxon 
matched paired signed ranks test. 
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Blood lipids analyses 
There was no significant difference between the starting levels of serum lipids in the two diet periods 
(Table 3-4). Serum total cholesterol concentration was reduced by 10.2% (P < 0.004) in the PS/DAG 
oil period compared to that of the control period (DAG oil). Serum total cholesterol concentration 
reduced by 7.6% during the PS/DAG oil period, and an increase of 2.5% was observed during the 
DAG oil period. LDL cholesterol was 12.1% (P < 0.003) lower after the PS/DAG oil treatment. 
Serum LDL cholesterol concentration reduced by 9.0% and increased by 3.1% in the PS/DAG oil and 
the DAG oil treatments, respectively. Serum HDL cholesterol and triacylglycerol did not change 
significantly after the PS/DAG oil. ApoB and Lp(a) were 9.7% lower (P < 0.001) and 18.6% lower (P 
= 0.023) after the PS/DAG oil, whereas no change was observed in apoAI. 
Individual data for changes in serum LDL cholesterol and Lp(a) concentrations between the 
two periods are shown in Fig. 3-2. In addition, a significant negative correlation was found between 
the changes in serum Lp(a) concentrations in the PS/DAG oil period and the baseline serum Lp(a) 
concentrations (R = -0.661, P < 0.05, Fig. 3-3). 
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Fig. 3-2  Individual data for changes in serum LDL cholesterol and Lp(a) concentrations in the two 
diet periods (n = 14) 
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Fig. 3-3  Correlation between baseline serum Lp(a) concentrations and variations in serum Lp(a) 
during the PS/DAG oil period (n = 14) 
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Other blood parameters analyses 
Serum concentrations of noncholesterol sterols and their levels relative to total cholesterol are 
shown in Table 3-5. During the PS/DAG oil period, serum β-sitosterol, campesterol and lathosterol 
concentrations were not significantly changed, while the relative-to-total cholesterol levels were 
significantly increased. The correlation between serum cholesterol reduction by the PS/DAG oil 
treatment and baseline characteristics of the subjects with regard to intestinal absorption and de novo 
synthesis levels was investigated. The changes in serum total cholesterol concentrations were 
negatively correlated with baseline ratios of serum lathosterol to total cholesterol, an index of 
cholesterol synthesis (R = -0.608, P < 0.05), although not significant with baseline ratios of serum 
campesterol to total cholesterol, an index of intestinal cholesterol absorption (R = 0.273, P = 0.345). 
No significant changes in serum TBA concentrations between two treatments were observed. 
There were no adverse indications in any of the physical or blood examinations: the indices 
of hepatic functions including AST, ALT, and γ-GTP (Table 3-6), and the female hormone parameters 
including estradiol and follicle-stimulating hormone (data not shown).  
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3.4  Discussion 
 
The primary objective of the present study was to examine the effect of the PS/DAG oil as a practical 
first-line therapy for the management of atherogenic blood lipoproteins in postmenopausal women 
(not obesity) before resorting to drug treatments. At the end of a four-week period of ingesting of 
PS/DAG oil, not only reductions in serum total (10.2%) and LDL (12.1%) cholesterols and apoB 
(9.7%) concentrations but also a reduction in serum Lp(a) (18.6%) concentration was induced (Table 
3-4, Fig. 3-2). DAG oil itself did not induce a cholesterol-lowering effect which is consistent with 
previous studies (Maki et al., 2002; Teramoto et al., 2004; Yamamoto et al., 2006).  
A large number of studies have used PS in a dosage range from 700 to 3,000 mg/day (Katan 
et al., 2003; St-Onge & Jones, 2003) and the effective minimum dose of PS dissolved in TAG oil has 
been estimated to be 800 mg/day or higher, worldwide (U.S. Department of Health and Human 
Services, 2000). Although it has been recommended that 2 g of PS/day should be consumed to 
achieve a cholesterol-lowering effect, Ostlund et al. (2002) reported that a unique formula of free 
stanols emulsified with lecithin was more effective in reducing cholesterol absorption at a small dose 
(300 mg/day) than previously believed. DAG can be found in hydrolysates of TAG and has been 
used to emulsify oils in processed foods in small amounts. Solubilization of PS in DAG oil has 
recently been proposed as a newer method of incorporating PS into food, compared to TAG oil with 
a similar fatty acid composition. Meguro et al. reported that PS, when solubilized in DAG oil, 
significantly reduced serum total and LDL cholesterols concentrations (PS: 500 mg/day) in men 
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(Meguro et al., 2001) and prevented the development of atherosclerosis in cholesterol-fed rabbits 
(Meguro et al., 2003) compared to a similar formulation in TAG oil, suggesting that the effect may be 
the result of the higher solubility of PS in DAG oil compared to TAG oil (6 vs. 1.3%, respectively). 
Furthermore, the effective minimum dosage of PS or PSE dissolved in DAG oil has been reported to 
be 400 mg/day (free PS equivalent) in Japanese men (Goto et al., 1999; Saito et al., 2006a). However, 
the effect of PS dissolved in 1-monoacylglycerol, a major component of the hydrolysate of DAG oil 
(Kondo et al., 2003) that possesses a strong emulsifying activity, on cholesterol and PS incorporation 
to biliary micelles remains to be addressed. 
In the present study, the cholesterol-lowering effect of the PS/DAG oil was more closely 
correlated with baseline cholesterol synthesis than cholesterol absorption, contrary to the previous 
sitostanol ester margarine study in postmenopausal women with CHD (Gylling et al., 1997). Based 
on a study by Rajaratnam et al. (2001), the cholesterol metabolism balance in postmenopausal 
women without CHD was reported to involve a higher baseline synthesis and a decreased absorption 
of cholesterol, compared to postmenopausal women with CHD. The differences in cholesterol 
balance due to the different of the two groups appear to be involved in the above discrepancy. The 
identification of mutations in ATP binding cassette transporters in sitosterolemia and experiments 
using transgenic mice has greatly expanded our knowledge of cholesterol transport in the small 
intestine and liver. Plat and Mensink (2002b), using Caco-2 cells, proposed that PS possibly enhance 
cholesterol efflux back into the intestinal lumen, but other effects on cholesterol efflux from liver and 
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bile metabolism are unknown. In general, the bile is comprised of ∼82% of water, 12% of bile acids, 
4% of phospholipids, 1% of free form of cholesterol and 1% of proteins in humans. The primary bile 
acids are C24-sterol derivatives synthesized from cholesterol (Bloch et al., 1943) such as cholic acid 
and chenodeoxy-cholic acid (trimming 3 carbons from the side chain of cholesterol), and are 
conjugated especially with glycine or taurine (Zwicker & Agellon, 2013). Bile acids including 
conjugated forms are released from the gallbladder after each meal, and help absorb fat including fat 
soluble vitamins as detergents in the intestine. Subsequently, more than 95% of the bile acids are 
reabsorbed in the intestinum ileum. Because of the main pathway of cholesterol metabolism 
(cholesterol elimination from the body), the synthesis of bile acids from cholesterol in the liver is 
tightly regulated to recover a loss due to the excretion to the stool (∼0.5 g/day).  
 A famous cholesterol-lowering resin such as cholestyramine (e.g. Questran) strongly binds 
bile acids in the intestine and excretes them into the stool. As a result of this removal of bile acids, 
more cholesterol is converted to bile acids and normalises blood cholesterol concentration. In the 
present study, serum TBA concentration did not change, suggesting that there were no impacts of 
PS/DAG oil on enterohepatic circulation of bile acids (total bile acid pool) and absorption of fat 
soluble vitamins (Chapter 4). Therefore, the results in the present study imply that cholesterol efflux 
from the liver depends on cholesterol synthesis and the subsequent effective inhibition of only 
cholesterol reabsorption (not affect bile acids) in the small intestine by PS may contribute to the 
reduction in blood cholesterol concentrations; however, the exact mechanism of action of PS on ATP 
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binding cassette transporters needs to be investigated further. 
Recently, it has been reported that bile acids interact with a G protein-coupled receptor, 
TGR5, expressed in various tissues including brown adipose tissue, immune system, skeletal muscle, 
nervous tissue and large intestine, linked to signalling pathway for the energy metabolism (Watanabe 
et al., 2006). Bile acids also promote Glucagon-like peptide 1 (GLP-1) release from the intestinal 
L-cells via the TGR5 activation, which contributes to the antiobesity effect due to inhibitions of 
gastric emptying and food appetite (Pols et al., 2011). In the present study, it is assumed that the DAG 
oil consumption did not change serum TBA concentration since the test period was too short to 
evaluate the antiobesity effect (4 weeks). Thus, further long-term studies are needed to explore a 
relationship between food ingredients intake and biomarkers such as bile acids and TGR5 levels. 
Lp(a) has been linked to an increased risk of heart disease and stroke (Armstrong et al., 1986). 
Upon reaching menopause, serum Lp(a) concentrations become sharply elevated by 15% to 25% 
compared to that of premenopausal women, which partially correlates with the incidence of CHD in 
elderly women, since Lp(a) may interfere with the thrombolytic process (Jenner et al., 1993). A lack 
of estrogen suppresses the expression of LDL receptors in the liver, resulting in a sudden elevation in 
serum LDL particles; however, the mechanism responsible for this change in Lp(a) metabolism is not 
clearly understood. Teramoto et al. reported that the long-term ingestion of DAG oil improved serum 
Lp(a) concentrations in patients on hemodialysis, which may be a consequence of decreased hepatic 
fat, as evidenced by reduced levels of abdominal fat (Teramoto et al., 2004). On the other hand, 
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Thomsen et al. (2004) reported that serum Lp(a) concentration was not affected by the consumption 
of PS (1.2 and 1.6 g/day) for 4 weeks in subjects with hypercholesterolemia, although the baseline 
serum Lp(a) concentration was relatively higher (39 mg/dL). In the present study, a slight but 
significant reduction in serum Lp(a) concentration was observed during the PS/DAG oil period alone 
without reducing body weight, especially, in subjects with higher levels of baseline serum Lp(a) (>20 
mg/dL), analogous to nicotinic acid (Teramoto et al., 1996) and fish oil (Beil et al., 1991) (Fig. 3-3), 
although this was not found during the DAG oil period. These results suggest that the reduction in 
serum Lp(a) in the present study may be caused by a synergistic effect between PS and the DAG oil; 
however, whether a combination of PS and the DAG oil affects serum Lp(a) concentrations through 
modification in catabolism or synthesis of Lp(a) particles, needs to be investigated. 
The normal range of serum PS concentration (β-sitosterol and campesterol) relative to the 
total cholesterol concentration (the ratio of PS to total cholesterol) is known to be less than 1% 
(Hidaka et al., 1990; Salen et al., 1992; Stalenhoef et al., 2001). In the present study the ratios of serum 
β-sitosterol/total cholesterol and campesterol/total cholesterol were mildly but significantly increased 
by 26% and 31% during the PS/DAG oil period (Table 3-5); however, the ratio of serum PS to total 
cholesterol at the end of PS/DAG period was also within the normal range (< 1%). There were no 
significant changes in liver functions (Table 3-6), female hormone parameters, although serum 
lathosterol/total cholesterol ratio (cholesterol synthesis) was slightly but significantly increased by 
13% as a feed back action via the inhibition of intestinal cholesterol absorption by the PS/DAG oil 
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(Table 3-5) as previous described (Gylling et al., 1999). These results indicate that the 4-week 
ingestion of PS/DAG oil pose no safety issues in postmenopausal women, although the 
cholesterol-lowering effect observed in the present study may be relatively mild compared to a 
previous study using the margarine (TAG oil) with PSE or plant stanol esters (Katan et al., 2003; 
St-Onge & Jones, 2003). 
Previous nutritional studies of DAG oil have shown unique characteristics such as antiobesity 
and an improvement in fasting hypertriglyceridemia (Nagao et al., 2000; Maki et al., 2002; Teramoto 
et al., 2004; Yamamoto et al., 2006); however, no significant changes in these parameters were 
observed in the present study. The reason for this may be that subjects with hypertriglyceridemia or an 
obese population were a small minority in the present study and the test period was relatively short.  
In conclusion, the present findings indicate that the PS/DAG oil is effective in reducing serum 
Lp (a) concentration as well as total and LDL cholesterols, apoB concentrations and apoB/AI ratio in 
postmenopausal women with mild to moderate hypercholesterolemia, without harmful influence on 
bile acids in the intestine that transport fat soluble vitamins. PS/DAG oil may be a useful adjunct to 
first-line therapy for the management of atherogenic lipoproteins in women after menopause. 
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CHAPTER 4 
 
Reciprocal effects of combined use of diacylglycerol oil and phytosterols on 
cholesterol metabolism in abdominal obesity 
 
4.1  Introduction 
 
Obesity, especially intra-abdominal (visceral) obesity, is a multiple risk factor for lipidemia, type 2 
diabetes and CVD (Matsuzawa et al., 1996). Visceral fat accumulation also may enhance blood 
atherogenic lipoprotein concentrations such as low-density lipoprotein (LDL) via hepatic lipoprotein 
overproduction. Although diacylglycerol (DAG) oil consumption reduces visceral fat accumulation, 
its effects on blood LDL concentrations have yet to be evaluated.  
Chapter 2 and 3 show the widely cholesterol-lowering effects of PS/DAG cooking oil in 
men and postmenopausal women with elevated blood cholesterol. In this Chapter, it is discussed the 
reciprocal benefits of well-regulated combined consumption of dietary DAG oil and PS as a 
mayonnaise-type food on body fat accumulation and blood lipids in overweight/obese middle-aged 
men. Compared to dietary TAG oil (control), DAG oil and PS/DAG oil significantly reduce body 
weight and visceral fat area at the umbilical level as measured by computed tomography (CT). 
Consumption of DAG oil alone slightly, but significantly, reduces blood cholesterol concentrations 
depending on a reduction in abdominal fat. These findings suggest that DAG oil functions not only as 
an advantageous delivery vehicle for PS, but also as an anti-atherogenic ingredient in combination 
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with PS especially in an overweight/obese population with increased visceral abdominal fat levels. 
 
 
4.2  Material and methods 
 
Study design 
This study was a randomized, double-blind, placebo-controlled, 3-arm intervention parallel trial (Fig. 
4-1). The study was performed under the supervision of an occupational health physician, in 
accordance with regulations of the Kao Corporation Ethics Committee for Internal Clinical Studies 
and in conformity with the Helsinki Declaration. The conditions and procedures of the investigation 
were reviewed with all subjects before they gave written informed consent.  
 
Subjects 
In Kao Corporation, 70 healthy overweight/obese middle-aged male volunteers (25-51 y) with no 
history of CHD or strokes were recruited. Subjects were excluded if they had poor blood sugar control, 
type 2 diabetes, hepatobiliary disorders, intolerance to PS or drug therapies for hyperlipidemia and 
diabetes. 
 
Experimental methods 
Prior to a test period, all subjects underwent a 2-week run-in period, and were instructed to have a 15 
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g package of control mayonnaise made of TAG oil daily as training. Then, the subjects were 
randomly assigned to one of three groups who ingested a 15 g package of mayonnaise comprised of 
either TAG oil, DAG oil, or DAG oil containing a mixture of PSE and PS (4 wt% as a free form, 
PS/DAG oil) for 16 weeks. 
The subjects were instructed to maintain 20-25% of fat energy ratio and not to exceed the 
recommended Japanese daily dietary energy (JMHLW, 1999). Daily alcohol intake was also limited 
to less than 30 g/day. During the study period, their physical habit and the activities were continued at 
the same levels as before the study. As shown in Fig. 4-1, fasting blood samples were collected from 
each subject a total of 6 times, prior to the run-in period (-2 week), at week 0, 4, 8, 12, 16 of the the 
treatment period. The subjects refrained from alcohol for 2 days prior to the examination. On the day 
before the examination, the subjects finished eating dinner by 21:00 except for drinking water. The 
blood sampling was conducted during fasting of 12 hours and more. CT scan was conducted at 0, 8, 
12 and 16 weeks. Compliance during the test period was checked by the remnants in mayonnaise 
packages before each examination visit. Daily dietary intake during the study was assessed by a 
national registered dietician, with 7-day record, based on the 5th revised Japanese Food Composition 
Table (JST, 2002). 
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Test food 
The DAG oil was prepared from soybean and rapeseed oils according to the method of Huge-Jensen 
et al (1988), and contained more than 80 g DAG (1,3-DAG:1(3),2-DAG = 7:3 wt/wt) / 100 g of oil 
(Saito et al., 2006b). The TAG oil (control) was prepared by mixing rapeseed, safflower and perilla 
oils to give a final acid composition that was similar to that of the DAG oil (Table 4-1). No 
appreciable differences in combustion energy between the DAG and TAG oils were previously 
reported (Taguchi et al., 2001). The PS/DAG oil was prepared to add in PSE acids and PS at a molar 
ratio of 3:1 (mol/mol) on the basis of the DAG oil and contained 4.2 wt% of PS in terms of a free 
form (β-Sitosterol: 2.1, Stigmasterol: 0.7, Campesterol: 1.2, Brassicasterol: 0.2 in wt%), while the 
DAG and TAG oils contained 0.3 and 0.5 wt% of PS, respectively. The three mayonnaise-type 
product used was prepared with TAG oil, DAG oil, or PSDAG oil according to the method of Saito et 
al. (2006b). All mayonnaise samples were packed at 15 g/package containing 10 g of test oil and were 
not distinguishable by appearance or taste. Each subject consumed one package containing 15 g/day 
at any time of the day for 16 wk. 
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Fig. 4-1  Diagram of the study design 
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Table 4-1  Composition of acylglycerols and fatty acids in test oils (wt%) 
  TAG oil   DAG oil  
Acylglycerols   TAG 98.4   11.9   
 DAG 1.4   87.1   
 MAG 0.2   1.0   
Fatty acids     C16:0 5.7   3.1   
 C18:0 2.2   1.3   
 C18:1 36.2   37.8   
 C18:2 46.7   48.6   
 C18:3 8.2   8.5   
 C20:1 0.9   0.7   
Oils contain triacylglycerol, TAG; diacylglycerol, DAG; monoacylglycerol, MAG. 
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Anthropometry measurements 
Body weight, waist circumference, and hip circumference were measured in each visit. Waist 
circumference at the umbilical level was measured while the subjects were standing. Within 3 days 
after the anthropometric measurements, the subjects underwent CT imaging (PRATICO, Hitachi 
Medical Corporation, Tokyo) of the abdominal transverse section at the umbilical level (L4-L5) at 
Wakayama Wellness Foundation (Wakayama, Japan) (Tokunaga et al., 1983). The X-ray conditions 
were tube voltage of 120 kVp and mAs of 200; the film was processed at a window level of 0 and a 
window width of 1000. CT imaging was performed by CT value in the range of -70 to -150 (scan 
time: 1 sec). The visceral fat area (VFA) and subcutaneous fat area (SFA) were obtained from the 
abdominal CT image, and these areas were summed to obtain the total fat area (TFA). The 
investigator who performed the scans and analyzed the data was blind to treatment assignment and 
clinical status of all subjects throughout the study. 
 
Blood Analyses 
Blood samples were collected from fasting subjects via a vein on the flexor side of the arm between 
09:00 and 10:00. Serum were obtained by centrifugation at 1,500 ×g for 15 minutes at 4°C, and stored 
at 4°C or -80°C. All anlyses, except for serum noncholesterol sterols, were conducted by SRL Inc. 
(Tokyo, Japan) Serum total, LDL and HDL cholesterols and triacylglycerol were measured using an 
enzyme assay, respectively. Serum apoB was measured using an immunonephelometric kit. Plasma 
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fibrinogen, serum AST, ALT and γ-GTP activities and creatinin were measured using an enzyme 
assay, respectively. Serum urea nitrogen was measured by urease UV method. Serum campesterol (an 
index of intestinal cholesterol absorption levels) (Miettinen et al., 1995; Tilvis & Miettinen, 1986), 
β-sitosterol, and lathosterol (an index of hepatic cholesterol synthesis levels) (Miettinen et al., 1990)  
concentrations were analyzed by gas-liquid chromatography on a DB-5HT column (15 m × 0.25 mm, 
J&W Co., USA) using saponified serum extract as trimethylsilyl derivatives (Saito et al., 2006a). 
These sterols were quantified using 5α-cholestane as the internal standard. Serum fat-soluble vitamins 
(retinol and α-tocopherol) and (α+β)-carotene concentrations were analyzed according to the method 
of Saito et al. (2006b). All parameters were measured in a blind manner. 
 
Statistical analyses 
A power calculation was performed to determine the required number of subjects. A sample size of 18 
subjects would have a power of 80% to detect a difference of ≈ 10 cm2 in visceral fat area with α = 
0.05. Data are presented as means ± standard error (SE) for descriptive purpose and mean [95% 
confidence interval (CI)] for inference. Baseline data are defined as the average of week -2 and 
randomized visit. The end point was defined as the average of the weeks 12 and 16. Changes and 
percent changes from baseline for each parameter were analyzed as below. Differences from baseline 
to end-point within the group were analyzed by Student’s paired t-test. Differences among three 
groups for body and blood lipid parameters at each point (4, 12, 8 and 16 weeks) and end-point were 
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analyzed using one-way analysis of variance (ANOVA) followed by Fisher's protected least 
significant difference (LSD) test. Differences within the treatment periods from baseline to 16 weeks 
among three groups for variables were analyzed using two-way repeated ANOVA followed by 
Fisher's protected least significant difference (LSD) test. Correlation coefficients were assessed using 
Pearson’s correlation test. A type I error rate of < 0.05 was considered to be statistically significant. 
The statistical analyses were performed using SPSS (11.0 for Windows, SPSS Inc., Chicago, IL). 
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4.3  Results 
 
Subjects and profile 
A total of 70 overweight/obese middle-aged male subjects participated in the study. Three moderate 
hypercholesterolemic subjects with lack of stability in blood cholesterol concentrations during run-in 
period and a subject with type 2 diabetes were excluded. Five subjects with the marked changes in 
their living environment and four subjects with low compliance for the test mayonnaises (frequency in 
use < 75%) during the study were also excluded. There were no significant differences between 
before and after the exclusion for the baseline profiles. Finally, data for 57 subjects were analyzed as a 
per protocol. The baseline profiles for the subjects in each group are shown in Table 4-2. There were 
no significant differences at baseline variables among the groups.  
 
Diet survey 
Frequency in use of the test mayonnaise packages in each group was ≥ 95%. Mean daily energy 
intakes at baseline and end-point were TAG group, 8.5 kJ and 8.9; DAG group, 8.5 and 8.5; PS/DAG 
group, 8.7 and 8.5. Mean fat intake of the energy at baseline and end-point were TAG group 26% and 
26%; DAG group, 27% and 26%; PS/DAG group, 27% and 28%. The energy and fat intakes were 
close to the standard of Japanese men (20-50 y) (JMHLW, 2004). No significant differences were 
shown in nutritional variables among groups throughout the study period (Fig. 4-2). No significant 
differences among groups were shown in others such as protein, carbohydrate, fiber and cholesterol.  
 82 
 
 
 
 
 
 
Table 4- 2  Clinical characteristics of the subjects at baseline 1 
  TAG   DAG  PS/DAG  
Age (years)  37.1 ± 2.0  36.3 ± 1.3  37.8 ± 1.4  
Male  18  21  18  
Body weight (kg)  69.2 ± 1.4  71.9 ± 1.6  73.4 ± 2.4  
BMI (kg/m2)  24.0 ± 0.5  24.1 ± 0.5  24.8 ± 0.7  
Waist (cm)  83.0 ± 1.2  84.5 ± 1.3  85.8 ± 1.8  
TFA (cm2)  189.0 ± 17.1  204.2 ± 13.3  210.6 ± 23.9  
VFA (cm2)  69.8 ± 8.6  67.8 ± 5.4  68.1 ± 8.3  
SFA (cm2)  119.3 ± 11.8  136.4 ± 10.5  142.5 ± 17.2  
Total cholesterol (mmol/L)  5.36 ± 0.23  5.23 ± 0.15  5.21 ± 0.20  
LDL cholesterol (mmol/L)  3.33 ± 0.16  3.31 ± 0.14  3.34 ± 0.16  
HDL cholesterol (mmol/L)  1.45 ± 0.08  1.33 ± 0.05  1.34 ± 0.06  
Triacylglycerol (mmol/L)  1.17 ± 0.12  1.35 ± 0.14  1.22 ± 0.16  
1 Values are the means ± SE. At baseline, there were no significant differences among groups in all variables 
using ANOVA followed with Fisher’s protected least significant difference (LSD). 
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Fig. 4-2  Dietary composition throughout the test periods   
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Anthropometry parameters analyses 
Anthropometric values and body composition at baseline and the percentage changes from baseline to 
each time point (week 4, 8, 12 and 16) and the end-point (average of week 12 and 16) of the study 
according to study group are shown Table 4-3 & 4-4 and Fig. 4-3 & 4-4. At baseline, anthropometric 
values and body composition were not significantly different among three groups. At weeks 12, the 
responses for the major variables in the DAG and PSE/DADG groups appeared plateau. In the DAG 
and PS/DAG groups, body weight were 2.6% (P < 0.01) lower and 1.6% (P = 0.069) lower than 
values in TAG group at the end-point, respectively. At the end-point, abdominal TFA of the DAG and 
PS/DAG groups were 12.7% (P < 0.01) lower and 9.4% (P < 0.05) lower than values in TAG group, 
respectively. VFA of the DAG and PS/DAG groups were 10.9% (P < 0.05) lower and 10.3% (P = 
0.058) lower than values in TAG group, respectively. SFA of DAG and PS/DAG groups were 
reduced by 14.2% (P <0.01) lower and 8.5% (P = 0.086) than values in TAG group, respectively.  
 
Blood lipids 
Serum concentrations of lipids and apos at baseline and the percentage changes from baseline to each 
time point (week 4, 8, 12 and 16) and the end-point are shown Table 4-5. At baseline, all serum 
concentrations of lipids and apos were not significantly different among three groups. The responses 
for serum total and LDL cholesterols and apoB concentrations in the PSE/DADG and DAG groups 
appeared plateau around at week 12. Their responses at the end-point among three groups were highly 
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significant in the PS/DAG and DAG groups. Pairwise comparison showed that serum LDL 
cholesterol and apoB concentrations were significantly lower by -11.2 (P < 0.01) and -8.4% (P < 0.05) 
in the PS/DAG group than TAG group. In the DAG group, serum LDL cholesterol and apoB 
concentrations were lower by -6.5% (P = 0.066) and by -4.1% (not significant) than control group at 
the end-point. No significant differences were shown in serum HDL cholesterol and triacylglycerol 
concentration in each group during the test period. 
Furthermore, at the end-point, changes in serum cholesterol parameters of the PS/DAG 
group were closely correlated with baseline serum campesterol concentrations, index of cholesterol 
absorption (total cholesterol: R = -0.811, P < 0.001; LDL cholesterol: R = -0.437, P = 0.070; apoB: R 
= -0.600, P < 0.01), not baseline serum lathosterol, index of cholesterol synthesis (total cholesterol: R 
= -0.324, P = 0.189; LDL cholesterol: R = -0.292, P = 0.240; apoB: R = -0.115, P = 0.649). In contrast, 
no relationship between the changes in apoB and the changes in VFA was shown in PS/DAG group 
(R = -0.338, P = 0.170). Interestingly, at the end-point, changes in serum cholesterol parameters of the 
DAG group were not correlated with baseline serum campesterol or lathosterol concentrations; 
however, positive correlation between the changes in apoB and changes in VFA was observed (R = 
0.484, P < 0.05) (Table 4-6). 
  
 86 
 
 
Other blood parameters analyses 
The effects of DAG and PS/DAG oils on the biochemical marker including liver function, fat-soluble 
vitamins and noncholesterol sterols were examined in Table 4-7. No significant differences between 
groups were observed in the blood safety markers including liver and kidney functions, fat-soluble 
vitamins (retinol, α-tocopherol and carotenes). Serum PS (sum of campesterol and β-sitosterol) 
concentrations in the PS/DAG oil group were maintained at < 0.045 mmol/L, and the ratios of serum 
PS to total cholesterol concentrations were also <1% throughout the present study. Serum lathosterol 
concentration was not significant among the groups. Fat-soluble vitamin concentrations in serum 
were within reference ranges at baseline and after treatment and were not affected by all of the 
treatments (Table 4-7). There were no significant differences among groups for hematology, general 
biochemical indexes marker. No adverse events were observed for any of the subjects. 
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Fig. 4-3  Changes in anthropometric parameters throughout the test periods   
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Fig. 4-4  Changes in abdominal fat parameters throughout the test periods   
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Fig. 4-5  Correlation between baseline visceral fat area and variations in visceral fat area in the three 
groups  
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Fig. 4-6  Changes in serum cholesterols and apoB throughout the test periods   
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Table 4-6  Relationship between blood cholesterol and abdominal parameters   
 
 
 
 
 
 
 
 
TC, total cholesterol; VFA, visceral fat area.
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4.4  Discussion 
 
In the present study, the combined treatment of DAG oil and PS as a mayonnaise under 
on the Japanese recommended dietary guideline are very beneficial in the management 
of abdominal fat and atherogenic blood parameters such as LDL cholesterol and apoB in 
Japanese overweight or obese middle aged men. No serious adverse events were 
observed throughout the test periods.  
Both the DAG and PS/DAG groups showed significant reductions in TFA 
(-17.6% and -14.3%) and VFA (-17.2% and 16.6%), respectively, compared to the TAG 
group (Table 4). These results were quite similar to the previous results of DAG oil 
conducted by Nagao et al. (2000). In the both DAG and PS/DAG groups, a significant 
negative correlation was also observed between changes in VFA and baseline values, 
respectively (Fig. 4-5), suggesting that the VFA-lowering effect attributable to DAG oil 
depends on the baseline visceral fat stored. Thus, the VFA-lowering effect of the DAG 
and PS/DAG groups would be expected in abdominal obesity with increased visceral fat 
accumulation. 
National Cholesterol Education Program (NCEP) in the U.S. (2002) has 
recommended the use of PS consisting of Δ5-PS (‘sterols’) and 5α-reduced PS 
(‘stanols’), to lower blood LDL cholesterol concentrations by ≈10%. The PS/DAG oil 
showed substantial cholesterol-lowering effect (LDL cholesterol: -11.2% and apoB: 
-8.4) than TAG, closely associated with the cholesterol absorption index, which is a 
reasonable response and consist with previous reports with sitostanol ester margarine 
(Gylling et al., 1997) and previous studies using PS/DAG oil (free form PS 400 to 500 
mg/day) as a cooking oil (Goto et al., 1999; Takeshita et al., 2001; Takeshita et al., 
2007a) or mayonnaise (Meguro et al., 2001; Saito et al., 2006a 174; Takeshita et al., 
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2007b) (Table 4-5). 
Because PS generally could block the cholesterol absorption in the small 
intestine, the cholesterol-lowering response of PS may be stronger in cholesterol high 
absorber. Thus, the impact of PS on the obese population were considered to be less 
likely effective than that of non-obese population, because cholesterol absorption 
efficiency is lower and cholesterol synthesis is higher in obese population. On the other 
hand, the DAG oil exerted a mild, but significant reduction in serum apoB concentration 
by ∼4%, depending on reducing visceral fat area (R = 0.484, P = 0.026) (Table 4-6). 
These results imply that the DAG oil could be partly involved in the lowering of VLDL 
production in the liver via a visceral fat reduction. This hypothesis is largely consistent 
with the report of Riches et al. (2007) and Simonen et al. (2002). It has been reported in 
visceral obesity that apoB-containing lipoproteins concentrations are elevated, and apoB 
may independently predict coronary risk (Lamarche et al., 1998; Sniderman et al., 2003). 
Thus, DAG oil has a new potential for support dyslipidemia resulted from visceral 
obesity or metabolic syndrome. DAG oil and PS could separately ameliorate a balance 
of cholesterol metabolism due to different mechanisms. However, cholesterol-lowering 
effect of DAG oil is needed to examine the mutual effects in detail.  
The average amount of PS intake during normal meals is from 150- 450 
mg/day, and trace amounts of PS exists in the blood of normal to hyperlipidemia (Salen 
et al, 1992). A recent study suggests that absorption and excretion of PS in the intestinal 
tract and excretion from the liver to bile, is functioned via ABCG5 and ABCG8 (Berge 
et al., 2000). In the present study, while serum concentration PS (the total of 
campesterol and β-sitosterol), especially campesterol, significantly increased from the 
baseline in the PS/DAG group (Table 4-7), serum PS concentration remained less than 
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1% of the total cholesterol concentration throughout the entire study period, as 
previously reported by Saito et al. (2006a), suggesting observed changes are within the 
normal range (Miettinen et al., 1995). 
With regard to the safety of PS, the effects on absorption of fat-soluble 
vitamins and carotenes within the intestinal tract have been previously discussed in the a 
meta-analysis of 18 clinical trials conducted by Katan et al. (2003). It was reported that 
a continuous consumption of 1.5 g/day or more PS or stanol had a significant reduction 
in serum concentrations of α-tocopherol, α-carotene and β-carotene. Meanwhile, no 
changes in serum fat-soluble vitamins (A, E and D) were observed during a 3-month 
continuous consumption of DAG oil (20 g/day) compared to that of TAG oil (Watanabe 
et al., 2001). In the present study, changes in serum retinol and α-tocopherol 
concentrations were not significant among groups and both were a normal range of 
fluctuations (Table 4-7). There was also observed no significant change in 
(α+β)-carotene. The above effects observed in the PS/DAG group were weaker than 
those reported in the United States and Europe (Katan et al., 2003), and may be 
attributable to the lower dose of PS. Accordingly, a long-term consumption of PS/DAG 
oil (PS: 400 mg/day) would have lesser impact on the intestinal absorption of 
fat-soluble vitamins and carotenes. 
In conclusion, a continuous combined ingestion of DAG oil and active form of 
PS can together ameliorate both visceral fat accumulation and elevated blood LDL 
cholesterol concentration including particle numbers of LDL (apoB), the major risk 
factors leading to CVD. 
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CHAPTER 5 
 
Rational benefits of combined use of a cholesterol biosynthesis 
inhibitor and dietary phytosterol-rich diacylglycerol oil  
 
5.1  Introduction 
 
Hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), which 
block the rate-limiting step of cholesterol biosynthesis (Fig. 5-1), greatly reduce blood 
low-density lipoprotein (LDL) cholesterol concentrations by 25% to 60% (Shepherd et 
al., 1995; Downs et al., 1998; 4S Group, 1994; Sacks et al., 1996; LIPID study Group, 
1998; Nakamura et al., 2006). Statins are the first-choice of cholesterol-lowering drug 
worldwide. Statin monotherapy is insufficient, however, for reducing blood cholesterol 
concentrations to target levels in hypercholesterolemic patients with increased intestinal 
cholesterol absorption (Miettinen et al., 2000). 
Chapters 1 through 3 showed the cholesterol-lowering effects of PS/DAG oil in 
healthy men and women before resorting to cholesterol-lowering drug treatments. This 
chapter demonstrates that the consumption of PS/DAG cooking oil reinforced low-dose 
pravastatin therapy initially prescribed in Japan, equivalent to doubling the dose of 
pravastatin, especially in persistent hypercholesterolemic outpatients. This finding 
suggests that these agents offset the negative feedback effects of the other (increased 
cholesterol absorption by statin (Miettinen et al., 2000) and increased cholesterol 
synthesis by PS (Gylling et al., 1997) and independently work via different mechanisms. 
Therefore, the use of PS/DAG oil in combination with typical statin therapy may 
represent a potential beneficial strategy for preventing CVD, especially in 
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hypercholesterolemic patients with a low response to statin due to increased cholesterol 
absorption, versus statin monotherapy. 
 
 
5.2  Material and methods 
 
Study design 
This study was a randomized, double-blind, 3-arm intervention parallel trial, and was 
performed as a multicenter study (Fig. 5-2): Mitsukoshi Health and Welfare Foundation 
(Tokyo, Japan), National Defense Medical College (Saitama, Japan), Nippon Medical 
School Chiba Hokuso Hospital (Chiba, Japan), and Nikko Memorial Hospital 
(Hokkaido, Japan). The protocol was permitted by each institutional review board in all 
facilities. All subjects participated in the study after giving informed consent, and the 
study was conducted ethically based on the spirit of the Helsinki declaration. All 
procedures such as registration and random division were independently carried out at 
the Mitsukoshi Health and Welfare Foundation. 
 
Subjects 
All eligible subjects were outpatients without history of CHD or stroke who were not 
sufficient to attain their target goals regarding blood concentrations of total and LDL 
cholesterols but were maintained stable specifically on low dose of pravastatin (10 
mg/day) during at least 4 weeks prior to beginning the study. Subjects were excluded if 
they had poor control of blood glucose concentration, hepatobiliary disorders and 
intolerance to treatments of pravastatin and/or PS.  
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Experimental methods 
All subjects were randomly divided to one of three groups consuming either TAG oil 
(control oil), DAG oil or DAG oil containing free forms of PS (4 wt%, PS/DAG oil). 
They were instructed to substitute their common cooking oils used at home for the test 
oil while continuing their pravastatin treatment (10 mg/day) for 12 weeks.  
The target dose of the test oil was assumed 10 g/day, which was the average 
consumption of cooking oil in Japan (JMHLW, 2002). Subjects were requested to 
maintain their usual isocaloric diets and physical activities at a constant level in the 
study. Fasting blood sampling was collected from all subjects three times, prior to the 
run-in period (-4 weeks), at week 0 and week 12, as shown in Fig. 5-2. All dietary data 
were delivered to the Health & Nutrition Institute, Snow Brand Milk Products Co., Ltd. 
(Tokyo, Japan) and a specific dietician independently analyzed the data during the study 
from at least two 24-hour dietary records using the computer software program 
"Healthy box" based on the 4th revised Japanese Food Composition Table (JST, 1998) 
in a blind manner. 
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Fig. 5-1  Mechanism of cholesterol synthesis inhibition by statin 
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Fig. 5-2  Diagram of the study design 
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Test oils 
PS/DAG oil (Econa H&H Cooking Oil ®, Kao Corporation, Tokyo Japan) was a 
functional cooking oil manufactured in Japan, permitted as a FOSHU for high blood 
cholesterol people by the Ministry of Health, Labour and Welfare of Japan. DAG oil 
(Econa Cooking Oil ®, Kao Corporation, Tokyo Japan) contained ~80 g DAG / 100 g 
(1,3-DAG:1(3),2-DAG = 7:3 wt/wt) and the main fatty acids of DAG oil were oleic acid 
and linoleic acid (C16:0, 2.4; C18:0, 0.7; C18:1, 28.0; C18:2, 61.2; C18:3, 7.4 wt%). 
PS/DAG oil contained 4.2 wt% of free forms of PS (β-Sitosterol, 1.87; Stigmasterol, 
1.22; Campesterol, 1.02; Brassicasterol, 0.11, in wt%) on the basis of the DAG oil, 
while the DAG and TAG oils contained 0.28 and 0.38 wt% of PS, respectively. TAG oil 
was prepared from a mixture of rapeseed oil and safflower oil (Nissin Oil Tokyo, Japan). 
This mixture was used to match the major fatty acid composition of DAG oil and 
PS/DAG oil as closely as possible (C16:0, 6.2; C18:0, 2.2; C18:1, 29.9; C18:2, 54.4; 
C18:3, 6.4 wt%). All test oils used in the study were very similar to ordinary cooking 
oils (TAG oil) in taste, flavor and appearance, which were indistinguishable from each 
other. 
 
Blood analyses 
Blood samples were collected from fasting subjects and serum samples were gained by 
centrifugation at 1,500 ×g for 15 minutes at 4°C, and stored at 4°C or -80°C. All 
analyses except for serum noncholesterol sterols were carried out by SRL, Inc. (Tokyo, 
Japan). Serum triacylglycerol, total cholesterol and HDL cholesterol were measured 
using an enzyme assay (Pureauto S TG-N, Daiichi Pure Chemicals, Co., Ltd., Tokyo 
Japan; L-type Wako CHO H, Wako Pure Chemicals, Inc., Osaka Japan; Cholestest N 
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HDL, Daiichi Pure Chemicals, Co., Ltd., Tokyo Japan). Serum LDL cholesterol was 
calculated by Friedewald's formula. Serum lipoprotein (a) [Lp(a)] was measured using 
an anti-human Lp(a) monoclonal antibody-coated latex preparation [Lp(a) Latex 
"DAIICHI", Daiichi Pure Chemicals, Co., Ltd., Tokyo Japan]. Serum apoB was 
measured using an immunonephelometric kit (Auto⋅N KIT series, Daiichi Pure 
Chemicals, Co., Ltd., Tokyo Japan). Plasma fibrinogen was measured using an enzyme 
assay (Fibrinogen a RD, Diagnostica Stago, France). Serum AST and ALT activities 
were measured using an enzyme assay kit (Transaminase-HR II, Wako Pure Chemicals, 
Inc., Osaka Japan). Serum γ-GTP activity was measured using an enzyme assay kit 
(Cicaliquid Gamma-GT J, Kanto Chemical of Tokyo Japan). Serum campesterol, an 
index of intestinal cholesterol absorption levels (Miettinen et al., 1995; Tilvis & 
Miettinen, 1986), β-sitosterol, and lathosterol, an index of hepatic cholesterol synthesis 
levels (Miettinen et al., 1990) were analyzed at the Kao Corporation by gas-liquid 
chromatography on a DB-5HT column (15 m × 0.25 mm, J&W Co., USA) using 
saponified serum extract as trimethylsilyl derivatives in a blind manner (Saito et al., 
2006a). As an internal standard for the quantitative determination of the sterols, 
5α-cholestane was used. 
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Statistical analyses 
The samples included data from all subjects whose baseline serum total cholesterol 
concentrations was not less than the standard borderline of the Japanese population (200 
mg/dL) and who retained compliance with pravastatin administration (≥ 75%) and the 
test oil dose (≥ 2 g/day) despite continuous pravastatin pretreatment (10 mg/day). 
Values are presented as the means ± SD. Changes in each parameter from the 
baseline values were analyzed using the paired t-test when the distribution of analytical 
values was normal or the Wilcoxon rank-sum test when the distribution was not normal. 
Changes in each parameter between groups were analyzed using one-way analysis of 
variance (ANOVA) followed with Bonferroni test. If the baseline values significantly 
differed between the groups, analysis of covariance (ANCOVA) was used. In the 
subclass analyses, the changes in lipid parameters between high serum campesterol 
group and low serum campesterol group on the basis of the median of the baseline 
serum campesterol concentration were analyzed using the Mann-Whitney U test. A type 
I error rate of < 0.05 was considered to be statistically significant. Correlation 
coefficients were assessed using the nonparametric Spearman’s rank correlation test. 
The baseline data are the average of the value before the start of the observation period 
and the value before the start of the test period. Statistical analyses were performed 
using SPSS version 11.0 (SPSS Inc., Chicago, IL).  
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5.3  Results 
 
Subjects and profile 
A total of 61 subjects participated in this study. Four subjects withdrew their consent 
and 57 completed 12-week intervention periods. Five subjects whose baseline serum 
total cholesterol concentration was < 200 mg/dL (5.17 mmol/L) were excluded. Eight 
subjects with a low compliance for taking pravastatin (< 75%, n=2) or consuming the 
test oil at home (< 2 g/day, n=6) during the test period were also excluded. Finally, data 
for 44 mildly to moderately hypercholesterolemic subjects (30-73 years, mean age 59 ± 
9 years) were evaluated. The initial clinical characteristics for all subjects in each group 
are shown in Table 5-1.  
The distribution of age (number and percentage) for the 44 subjects in each age 
group was 2 (4.5%) in the 30s, 2 (4.5%) in the 40s, 15 (34.1%) in the 50s, 20 (45.5%) in 
the 60s, and 5 (11.4%) in the 70s. The 50s-70s made up the main part (91.0%) and the 
average age among treatment groups did not differ significantly. The proportion of the 
subjects who received antihypertensive drugs was 23% (10/44). No subjects with the 
therapy of diabetes were observed. No changes in body weight and BMI were found in 
any of the groups (data not shown). 
 
Diet survey 
Total energy, fat, protein, carbohydrate, fiber, cholesterol and test oil intakes in each 
group did not change from the baseline to the 12 week-end point and the values at 12 
weeks were not significantly different between the groups (Table 5-2).   
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Table 5-1.  Initial profiles of the 44 subjects1 (total cholesterol ≥ 5.17 mmol/L) 1 
  
TAG oil 
(n=15) 
 
DAG oil 
(n=15) 
 
PS/DAG oil 
(n=14) 
 
Age (years)  58 ± 11  58 ± 6  61 ± 8  
  (30 to71)  (50 to73)  (45 to72)  
Male / Female  1 / 14  3 / 12  3 / 11  
Body weight (kg)  51.5 ± 5.7  53.5 ± 6.7  53.6 ± 10.7  
BMI (kg/m2)  21.8 ± 2.0  21.9 ± 2.1  21.8 ± 3.1  
1 Values are the means ± SD. 
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Table 5-2  Dietary composition of the 44 subjects during the test period 1 
  TAG oil  DAG oil  PS/DAG oil  
Energy (MJ/day) baseline 7.40 ± 1.34  8.10 ± 1.84  7.93 ± 0.61  
 12 wk 7.57 ± 0.97  7.72 ± 1.58  7.88 ± 1.09  
Fat (% of energy) baseline 25.6 ± 6.1  25.3 ± 7.5  29.2 ± 4.7  
 12 wk 27.4 ± 6.7  27.7 ± 6.0  27.7 ± 6.6  
Saturated baseline 8.2 ± 2.7  6.6 ± 2.6  9.1 ± 1.7  
  12 wk 8.3 ± 3.0  7.4 ± 3.0  8.0 ± 2.4  
Mono-unsaturated baseline 10.0 ± 2.7  10.0 ± 4.0  11.9 ± 3.1  
 12 wk 10.5 ± 2.9  11.0 ± 2.6  10.9 ± 2.6  
Poly-unsaturated baseline 7.5 ± 1.8  8.7 ± 2.4  8.2 ± 2.5  
 12 wk 8.6 ± 1.7  9.2 ± 2.4  8.8 ± 3.1  
Protein (% of energy) baseline 16.0 ± 2.4  16.0 ± 4.3  15.5 ± 2.9  
 12 wk 15.0 ± 1.4  14.8 ± 2.4  14.4 ± 2.8  
Carbohydrate (% of energy) baseline 56.8 ± 7.2  55.0 ± 9.5  53.4 ± 5.5  
 12 wk 56.2 ± 7.2  54.5 ± 6.3  54.9 ± 8.5  
Fiber (g/day) baseline 15.9 ± 4.0  18.3 ± 6.4  17.1 ± 4.9  
 12 wk 16.4 ± 5.6  16.6 ± 5.6  16.3 ± 5.6  
Cholesterol (mg/day) baseline 342 ± 144  222 ± 134   270 ± 126  
 12 wk 312 ± 202  256 ± 130  270 ± 156  
Cooking oil (g/day) baseline 9.6 ± 7.1  13.8 ± 12.1  13.0 ± 10.9  
 12 wk 12.8 ± 11.3  13.4 ± 8.5  11.9 ± 8.2  
Plant sterols from a cooking oil  baseline 36 ± 30  52 ± 46  49 ± 41  
(mg/day) 12 wk 49 ± 43 a  38 ± 24 a  502 ± 346 *, b  
1 Values are the means ± SD. * Significantly different from the baseline value by the paired t-test: 
* P < 0.01. Means in a row without a common letter differed significantly among groups by 
ANOVA followed by the Bonferroni test, P < 0.05.  
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In each treatment, the percentage of energy from fat was approximately 27%. 
The average consumption of test oil in each treatment group was approximately 12-13 
g/day, similar to the average daily intake of cooking oil (10 g/day) in Japan (JMHLW, 
2002). The average PS consumption from the PS/DAG oil was significantly greater 
(502 ± 346 mg/day, P < 0.05) compared to those for TAG and DAG oils (49 ± 43 and 38 
± 24 mg/day). Two smokers (< 20 cigarettes/day) participated in the study and tobacco 
consumption remained unchanged throughout the study. Twenty-two subjects had coffee 
constantly, but not more than 3 cups per day in the study. 
 
Blood lipids analyses 
In the PS/DAG oil group, serum total and LDL cholesterols and apoB concentrations 
were significantly lowered by 4.6% (P < 0.01), 5.2% (P < 0.05) and 6.4% (P < 0.01) 
from the baseline values (Table 5-3), respectively, although no significant differences 
between the groups was found.  
The data for females (n=11) were similar to those of the total subjects (n=14) 
[total and LDL cholesterols, -5.1% (P < 0.01) and -5.8% (P < 0.05); apoB, -7.6% (P < 
0.01) from the baseline values]. The effect of age on the percentage reduction in LDL 
cholesterol concentration was similar between 40s-50s and 60s-70s [-4.0% (n=5) and 
-5.5% (n=9), not significant between groups]. No such changes were observed in the 
TAG and DAG oil groups. In the PS/DAG oil group, the changes in serum LDL 
cholesterol concentrations were inversely correlated with the baseline serum 
campesterol concentrations (R = -0.560, P < 0.05, Fig. 5-3), but not significant with 
baseline serum lathosterol concentrations (R = -0.442, P = 0.114).  
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Table 5-3  Effects on serum lipids and lipoproteins in the three groups 1 
  TAG oil  DAG oil  PS/DAG oil  
Total cholesterol  Baseline 6.35 ± 0.94  6.27 ± 0.86  6.24 ± 0.64  
(mmol/L) 12 wk 6.41 ± 0.85  6.25 ± 0.96  5.96 ± 0.51 **   
LDL cholesterol  Baseline 3.94 ± 0.95  3.92 ± 0.83  4.04 ± 0.54  
(mmol/L) 12 wk 3.88 ± 0.85  3.95 ± 0.96  3.83 ± 0.49 *  
HDL cholesterol  Baseline 1.93 ± 0.44  1.80 ± 0.39  1.61 ± 0.44  
(mmol/L) 12 wk 1.93 ± 0.53  1.73 ± 0.44  1.56 ± 0.37  
Triacylglycerol  Baseline 1.05 ± 0.25  1.18 ± 0.41  1.30 ± 0.47  
(mmol/L) 12 wk 1.32 ± 0.55  1.25 ± 0.57  1.24 ± 0.46  
ApoB  Baseline 116 ± 18  121 ± 27  126 ± 18  
(mg/dL) 12 wk 114 ± 18  122 ± 31  118 ± 17 **  
Lp(a)   Baseline 37 ± 28  43 ± 51  47 ± 47  
(mg/dL) 12 wk 35 ± 30  41 ± 55  42 ± 39 *  
1 Values are the means ± SD. *, **  Significantly different from the baseline value by the paired 
t-test: * P < 0.05, ** P < 0.01. 
  
 112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5-3  Correlation between baseline serum campesterol concentrations and changes 
in serum LDL cholesterol concentration in the three groups 
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There were no significant correlations between the pretreatment values and changes in 
serum concentrations of LDL cholesterol (R = -0.415, P = 0.140) or apoB (R = -0.297, P 
= 0.303) in the case of PS/DAG oil treatment. No effect on serum triacylglycerol and 
HDL cholesterol concentrations was observed.  
The effects on serum cholesterol parameters were examined in subclass 
analyses, in which the 44 subjects were divided into two groups, based on the median 
(16.47 μmol/L) of their baseline serum campesterol concentrations (Table 5-4). Of the 
subjects with high baseline compesterol concentrations (HC: campesterol ≥16.47 
μmol/L), the serum total cholesterol concentration at 12 weeks was significantly lower 
in the PS/DAG oil by 9.4% compared to the TAG oil groups (P < 0.05), whereas no 
significant difference in the subjects with low baseline compesterol concentrations (LC: 
campesterol <16.47 μmol/L). In the PS/DAG oil group, serum LDL cholesterol and 
apoB concentrations were reduced to a greater extent in the HC versus LC subgroups 
[LDL cholesterol: -0.35 mmol/L (-13.4 mg/dL) vs. -0.08 mmol/L (-3.0  mg/mL) , P = 
0.064; apoB: -13.2 mg/dL vs. -3.1mg/dL, P < 0.05, Fig. 5-4]. The analysis of the female 
data was similar to above results (data not shown). 
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Table 5-4  Effects on serum cholesterol parameters between high (serum campesterol 
concentrations ≥ 16.47 μmol/L: HC) and low campesterol subgroups (serum 
concentrations < 16.47 μmol/L: LC) 1 
   TAG oil  DAG oil  PS/DAG oil  
Total cholesterol  HC baseline 6.72 ± 0.95  6.03 ± 0.42  6.31 ± 0.77  
(mmol/L)  12 wk 6.86 ± 0.59 a  5.94 ± 0.99 ab  5.89 ± 0.56 *, b  
 LC baseline 5.80 ± 0.64  6.42 ± 1.06  6.18 ± 0.53  
  12 wk 5.74 ± 0.75  6.45 ± 0.94  6.02 ± 0.49  
LDL cholesterol  HC baseline 4.19 ± 1.15  3.76 ± 0.64  4.03 ± 0.58  
(mmol/L)  12 wk 4.17 ± 0.89  3.73 ± 1.04  3.68 ± 0.43 *  
 LC baseline 3.57 ± 0.37  4.03 ± 0.96  4.05 ± 0.54  
  12 wk 3.44 ± 0.58  4.09 ± 0.94  3.98 ± 0.53  
ApoB (mg/dL) HC baseline 122 ± 21  114 ± 26  128 ± 20  
  12 wk 121 ± 18  119 ± 39  115 ± 17 *  
 LC baseline 107 ± 8  125 ± 28  125 ± 17  
  12 wk 105 ± 12  124 ± 27  121 ± 19  
Lp(a) (mg/dL) HC baseline 46 ± 31  58 ± 73  70 ± 55  
  12 wk 45 ± 33   58 ± 83  59 ± 47 *  
 LC baseline 25 ± 20  34 ± 31  25 ± 24  
  12 wk 20 ± 18 *  30 ± 25  24 ± 21  
1 Values are the means ± SD. * Significantly different from the baseline value by the paired t-test 
or the Wilcoxon rank-sum test: P < 0.05. Means in a row without a common letter differed 
significantly among groups by ANOVA or ANCOVA followed by the Bonferroni test, P < 0.05. 
HC subgroup: TAG (n=9) DAG (n=6) PS/DAG (n=7). LC subgroup: TAG (n=6) DAG (n=9) 
PS/DAG (n=7). 
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Fig. 5-4  Effect of the PS/DAG oil on serum apoB concentration between high (serum 
campesterol ≥ 16.47 μmol/L: HC, n=7) vs. low campesterol subgroups (serum 
campesterol < 16.47 μmol/L: LC, n=7) 
Values are means ± SD. † Significantly different between the HC and LC subgroups by the 
Mann-Whitney U test: P < 0.05. 
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Serum Lp(a) concentration was mildly but significantly decreased by 12.4% (P 
< 0.05) from the baseline value in the PS/DAG oil treatment and a highly inverse 
correlation was found between the changes in serum Lp(a) concentrations and baseline 
serum Lp(a) concentrations (R = -0.851, P < 0.001). A linear reduction in serum Lp(a) 
concentration was observed especially in subjects with higher levels of baseline serum 
Lp(a) (> 20 mg/dL). A similar relationship was observed in the DAG oil group (R = 
-0.541, P < 0.05), but not in the TAG oil group (R = 0.145, P = 0.607). Interestingly, 
there was a significant positive correlation between changes in apoB and changes in 
Lp(a) concentrations (R = 0.596, P < 0.05, Fig. 5-5) in the PS/DAG oil treatment. 
Serum Lp(a) concentrations in the PS/DAG oil treatment group were also reduced to a 
greater extent in the HC versus LC subgroups (-10.8 mg/dL vs. -1.0 mg/dL, P < 0.05), 
as well as LDL cholesterol and apoB.  
 
Other blood parameters analyses 
Serum campesterol and lathosterol concentrations were increased from the baselines by 
5.2 and 11.5% in the PS/DAG oil group, respectively, although these increases were not 
significant (Table 5-5). Serum PS (sum of campesterol and β-sitosterol) concentrations 
in the PS/DAG oil group were maintained at < 0.04 mmol/L. The ratios of serum PS to 
total cholesterol concentrations were also < 1% throughout the study.  
In both the DAG and PS/DAG oil groups, serum AST, ALT, γ-GTP and 
fibrinogen concentrations showed a tendency to be lower than those of the TAG oil 
group by 5-14 %, but the difference between the groups was not significant (data not 
shown). No adverse events such as myopathy and hepatotoxity were observed for any of 
the subjects.  
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Fig. 5-5  Correlation between changes in serum apoB concentrations and changes in 
serum Lp(a) concentration in the PS/DAG oil group (n=14) 
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Table 5- 5  Effects on serum PS and lathosterol in the subjects 1 
  TAG oil  DAG oil  PS/DAG oil  
Campesterol  Baseline 18.44 ± 5.27  18.47 ± 8.68  17.67 ± 4.49  
(μmol/L) 12 wk 18.72 ± 7.14  17.54 ± 7.46  18.59 ± 4.42  
β-Sitosterol Baseline 9.07 ± 2.60  9.55 ± 6.22  9.31 ± 2.89  
(μmol/L) 12 wk 9.28 ± 3.62  9.21 ± 5.96  8.51 ± 3.04  
Lathosterol  Baseline 7.40 ± 3.18  7.01 ± 3.23  6.54 ± 2.43  
(μmol/L) 12 wk 9.36 ± 4.71  7.55 ± 3.44  7.29 ± 2.25  
1 Values are the means ± SD. 
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5.4  Discussion 
 
The findings of the present study show that the practical use of dietary PS/DAG oil on a 
10 mg/day of pravastatin, as a low-dose combined therapy, is beneficial for further 
reducing, not only of blood cholesterols, but also Lp(a) concentrations in Asian 
hypercholesterolemic patients with a low response to pravastatin. The impact of 
PS/DAG oil was also closely associated with the initial serum campesterol 
concentrations.  
Statins and PS are the most widely used agents for treating hypercholesterolemia 
(Shepherd et al., 1995; Downs et al., 4S Group, 1994; Sacks et al., 1996; LIPID study 
Group, 1998; Miettinen et al., 2000; Nakamura et al., 2006; Miettinen et al., 1995; 
Katan et al., 2003; Ostlund et al., 2004; NCEP Expert Panel, 2002). However, there are 
populations that are intolerant to a high-dose statin, such as patients with impaired renal 
function and patients taking a concomitant fibrate or cyclosporine (Thompson et al., 
2003). Also, Asians generally achieve similar benefits to Westerners at lower statin 
doses (Nakamura et al., 2006; Liao, 2007). Recent pharmacokinetic studies of 
rosuvastatin have established a 2-fold elevation in median exposure (AUC and Cmax) in 
Asian compared to Caucasian (Liao, 2007) and the U.S. Food and Drug Administration 
has recommend that a low dose of the drug should be considered as the start dose for 
Asian patients (FDA, 2005; Saito et al., 2005). PS also have potentially negative effects 
on carotene absorption within the recommended dosage range (Katan et al., 2003; 
Richelle et al., 2004). Thus, in the present study, a combined use of pravastatin and PS 
at low doses was examined and a further 5% reduction in serum LDL cholesterol 
concentration was found in the PS/DAG oil treatment group. The effect observed here 
was milder compared to values reported in previous studies with standard-dose 
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combination (Gylling H, 1997; Blair et al., 2000; Neil et al., 2001; Cater et al., 2005; 
Gylling & Miettinen, 2002), but was equivalent to doubling the dose of pravastatin 
(Law et., 2003), which clearly indicates the clinical importance. 
Miettinen et al. (1995) demonstrated a substantial cholesterol-lowering effect of 
sitostanol-ester margarine and the reduction in total cholesterol concentrations was 
directly correlated with the reduction in serum campesterol concentrations, an index of 
intestinal cholesterol absorption. On the other hand, in the present study, the changes in 
serum LDL cholesterol concentrations in the PS/DAG oil treatment were inversely 
correlated with baseline serum campesterol concentrations (R = -0.560, P < 0.05, Fig. 
5-3). Of the subjects in the HC subgroup, a significant reduction by 9% in serum total 
cholesterol concentrations in the PS/DAG oil compared to TAG oil groups was shown 
(Table 4). Serum LDL cholesterol and apoB concentrations were also reduced to a 
greater extent in the HC versus LC subgroups (9-10% vs. 2-3%, Fig. 5-4), which is 
basically consistent with a previous result (Gylling & Miettinen, 2002). The agents used 
might reduce each other’s negative feedback effects (cholesterol absorption up by statin 
(Miettinen et al., 2000) and synthesis up by PS (Gylling et al., 1997) and independently 
and effectively work. According to data from drug trials, a 10% reduction in LDL 
cholesterol concentrations would be expected to reduce the incidence of ischemic heart 
disease by 12-20% over a 5 year period (Katan et al., 2003). Therefore, the present 
approach with the use of low-dose combination may be an attractive option for high 
cholesterol absorber, especially patients with intolerance to high-dose statin. 
A meta-analysis showed that supplementation with 2 g of stanols or sterols is 
desirable in terms of reducing LDL cholesterol concentration by ≈10% (Katan et al., 
2003). However, evidence to support that theory was concentrated close to the tail of the 
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dose-response curve. Ostlund et al. (2002) recently showed that natural PS in 
commercial corn oil and sitostanol emulsified with lecithin (Ostlund et al., 1999) are 
bioactive at very low doses (150-300 mg) in single meal tests. Shin et al. also confirmed 
that water-dispersible micellar PS (300 mg) had a similar impact on cholesterol 
absorption (Shin et al., 2005). Meguro et al. reported that PS, when solubilized in DAG 
oil induced the cholesterol-lowering effect in Japanese men (500 mg/day) (Meguro et al., 
2001) and the prevention of atherosclerosis in cholesterol-fed rabbits (Meguro et al., 
2003). The effective minimum dosage of PS or PS esters dissolved in DAG oil has been 
shown to be 400 mg/day in Japanese men (Goto et al., 1999; Saito et al., 2006a). Thus, 
highly bioavailable formulation of such agents (stanols and sterols) would have greater 
possibilities for developing the potential. 
The mechanism by which PS inhibit cholesterol absorption is not fully 
understood, but it appears that PS displace cholesterol from micelles and limit the 
amount of cholesterol absorption in the intestinal lumen (Ostlund et al., 2004). Recently, 
several studies have suggested that soluble forms of PS can interfere with the 
incorporation of cholesterol into micelles (Ostlund et al., 2002; Ostlund et al., 2004; 
Shin et al., 2005), but not insoluble forms (Ostlund et al., 1999; Denke, 1995). More 
recent studies using fat-free beverages containing PS indicate that the presence of a 
lecithin formulation and the degree of micellar PS dispersion appear to be involved in 
reducing blood LDL cholesterol concentrations (Spilburg et al., 2003; Jones et al., 2003). 
Meguro et al. (2001) also suggested that the higher solubility of PS in DAG oil versus 
that in TAG oil (6 vs. 1.3 wt%, respectively) may contribute to facilitating the action of 
PS. However, the effect of PS dissolved in 1-monoacylglycerol, a major hydrolysate of 
DAG (Kondo et al., 2003) that possesses a strong emulsifying activity, on biliary 
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micelles remains to be investigated. 
Lp(a) is known to be a risk factor of CHD via promoting atherogenesis 
(Berglund & Ramakrishnan, 2004); however, the exact metabolism of Lp(a) is unknown. 
So far, there are few reports showing that the blood Lp(a) concentration is ameliorated 
by the consumption of dietary PS (Garoufi et al., 2014; Plat & Mensink, 2000; Thomsen 
et al., 2004), the treatments of statins (Sahebkar et al., 2017), or the up-regulation of 
hepatic LDL receptor (Plat & Mensink, 2002a). However, Teramoto et al. reported that 
long-term use of DAG oil reduced serum Lp(a) concentrations via lowering abdominal 
fat (Teramoto et al., 2004). Previous animal studies have shown that 1, 3-DAG, the 
main ingredient of DAG oil, might retard TAG resynthesis in small intestinal epithelial 
cells (Kondo et al., 2003) and suppress hepatic microsomal triglyceride transfer protein 
activity compared to TAG oil (Taguchi et al., 2002). The suppression of hepatic fat 
accumulation has also been reported in animal (Taguchi et al., 2002) and human (Nagao 
et al., 2000) studies, suggesting that DAG oil could decline hepatic lipoprotein synthesis. 
In the present study, mild, but significant reduction in serum Lp(a) concentrations was 
revealed mainly in the PS/DAG oil treatment, depending on the baseline values (>20 
mg/dL), although body weight did not affect since the obese population was a small 
minority. The reduction in serum Lp(a) concentrations was closely associated with a 
reduction in serum apoB concentrations, a core component of Lp(a) (R = 0.596, P < 
0.05, Fig. 5-5). Recent meta-analysis of drugs have reported that fibrates promote the 
Lp(a)-lowering effect (Sahebkar et al., 2017). Therefore, the serum Lp(a) reduction 
observed here may have resulted from 1) lowering the hepatic synthesis of Lp(a) by 
1,3-DAG, similar to antihypertriglyceridemic agents such as nicotinic acid (Teramoto et 
al., 1996), fish oil (Beil et al., 1991) and fibrates (Sahebkar et al., 2017), and 2) 
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enhancing the catabolism of Lp(a) by PS. However, additional studies accompanied 
with DAG oil consumption will be required to address this issue.  
The absorption efficiency for PS in humans is considerably less than that of 
cholesterol (0.04-2% vs. 60 %) (Ostlund et al., 2004). Blood levels of PS (β-sitosterol 
and campesterol) in humans are maintained only at less than 1 % of cholesterol 
concentrations (Katan et al., 2003). The individual blood concentrations of PS in the 
PS/DAG oil treatment did not exceed this normal range throughout the study. There 
were no impaired liver function and other adverse effects.  
In conclusion, a low-dose combination of dietary PS/DAG and pravastatin is 
recommend as a beneficial treatment for further ameliorating blood cholesterols and 
Lp(a) concentrations especially for hypercholesterolemic patients with increased 
intestinal cholesterol absorption. DAG oil possibly ameliorates blood lipoproteins levels, 
but needs further clinical investigations. It is a therapeutic option to add in PS for a 
variety of population on statin.  
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CHAPTER 6 
 
General discussion 
 
6.1  Main findings in the present thesis  
 
Replacements of daily foods with functional foods may be a new gateway to health 
promotion. To demonstrate whether dietary PS/DAG oil benefits various types of 
subjects with hypercholesterolemia in the prevention of CVD, four prospective clinical 
studies were executed with the greatest care, as below.  
[1] PS/DAG oil consumption might sharply affect blood cholesterol 
concentrations and rebound after discontinuation, or abnormally raises blood PS 
concentrations, because of higher solubility for PS in DAG oil than TAG oil. Thus, a 
long-term practical study was examined in normal to hypercholesterolemia. As a result, 
long-term ad libitum replacement of cooking oil with PS/DAG oil brings out the robust 
cholesterol-lowering action in moderate to hypercholesterolemic population, not the 
normocholesterolemic population. In addition, PS/DAG oil possibly ameliorates blood 
concentrations of other atherogenic parameters including triacylglycerol, HDL 
cholesterol, RLP-C and PAI-1 (an inhibitor of fibrinolysis) due to an intake of DAG oil. 
No rebound and adverse effects including abnormal blood PS concentrations were 
shown in all clinical studies. 
 [2] Half of elderly women face an increased risk of blood atherogenic 
lipoproteins, because of estrogen depletion. Thus, it was precisely examined to evaluate 
effects of PS/DAG oil on blood lipids in postmenopausal women with elevated blood 
cholesterol in a crossover manner. As a result, it was found that dietary PS/DAG oil has 
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unique anti-atherogenic benefits for the management of high blood LDL cholesterol and 
Lp(a). PS dissolved in DAG oil, as well as that in TAG oil, possibly inhibit the intestinal 
absorption of both dietary and biliary cholesterols by displacing cholesterol from 
micelles, facilitating the excretion of cholesterol, but not bile acids. In increasingly 
aging era, PS/DAG oil may be useful for the prevention of CVD in elderly women. 
 [3] Long-term consumption of DAG oil possibly affects blood cholesterol 
concentration due to the anti-obesity effect, separately from PS, but not being addressed. 
Thus, to compare and analyze the interaction between DAG oil and PS, an exact 
intervention study was examined in middle-aged men with overweight/obesity. As a 
result, the consumption of DAG oil per se possibly suppresses the cholesterol synthesis 
in the liver by the smaller harmful visceral fat whose mechanism is different from that 
of PS. Simultaneous intake of dietary DAG oil and PS could efficiently ameliorate 
blood LDL cholesterol concentrations in obese population.  
 [4] Outpatients with low responder to major cholesterol-lowering drug (statin) 
need to increase in dose, but may produce side effects. Thus, it was examined whether 
additional intake of PS/DAG oil works as an adjunct to statin, or not. As a result, dietary 
PS/DAG oil clearly reinforced the cholesterol-lowering effect (doubling the dose of 
pravastatin) than stain monotherapy, in persistent hypercholesterolemic outpatients with 
low dose of statin. Also, PS/DAG oil consumption on the statin therapy facilitated to 
ameliorate other blood atherogenic parameters such as apoB and Lp(a). The combined 
use of functional food and drug could be a new therapeutic option.  
 DAG oil possibly ameliorates blood and hepatic lipid metabolisms mainly 
including cholesterol, fibrinolysis and visceral fat accumulation.   
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6.2  Challenges currently facing high blood cholesterol in Japan   
 
Based on the latest Nutrition Survey in Japan (JMHLW, 2016), it has been reported that 
numbers of cholesterol-lowering drug users have dramatically expanded from 2006 to 
2016, especially in the 60s, 70s and over in men and women (Fig. 6-2). The elderly 
populations in both sexes have grown as a volume zone in the market of cholesterol 
reducers. As a result, high blood cholesterol populations whose serum total cholesterol 
concentrations are not less than 6.21 mmol/L (≥ 240 mg/dL) have been concentrated in 
the 40s and 50s in men, and 50s and 60s in women regardless of the drug therapy.  
Cholesterol-lowering drugs have been developed as 3 types including statins, 
ezetimibe and bile acid sequestrants worldwide (Fig. 6-3). The cholesterol-lowering 
effects of statins, ezetimibe and bile acid sequestrants are by 20-60%, 20% and 10-20%, 
respectively. The combined uses of agents with different mechanisms (e.g. statin and 
ezetimibe) have been popular, because of efficiently achieving goal lipids levels with no 
adverse effects due to at each lower dose (Ambegaonkar et al., 2014). On the other hand, 
the averages of blood total cholesterol concentration in both sexes have not been 
changed from 2006 to 2016, respectively [5.09 mmol/L (= 197 mg/dL) to 5.09 mmol/L 
(= 197 mg/dL) in men; 5.25 mmol/L (= 203 mg/dL) to 5.28 mmol/L (= 204 mg/dL) in 
women]. Also, the rate of high blood cholesterol populations (≥ 6.21 mmol/L) at each 
generation is not significantly different through the decade, despite the increase in drug 
users year by year. In general, most drugs including cholesterol-lowering drugs will be 
limited in use for children and women with the chance of achieving pregnancy to avoid 
impermissible adverse effects. Thus, universally accepted ‘functional food’ that 
provides a lifetime of healthy blood cholesterol should be explored to prevent CVD.  
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Fig 6-2  Trend in the percentage of high blood cholesterol population and 
cholesterol-lowering drug users from 2006 to 2016 (JMHLW, 2016) 
 
 
 
  
 128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6-3  Cholesterol-lowering drugs and mechanism for LDL cholesterol reduction 
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6.3  Recent developments of functional foods for the prevention of CVD  
 
In Japan, ‘Foods for Specified Health Use’ (FOSHU) was established 1991 by the 
Japanese Ministry of Health, Labour, and Welfare (MHLW) as a regulatory system to 
approve the health claims based on the scientific evidence of the food on the human 
body. With regard to FOSHUs that manage high blood cholesterol, major 6 types of 
ingredients are permitted, as shown in Table 6-1.  
Major ingredients of FOSHUs in Japan that manage high blood LDL 
cholesterol concentration are PS, soy protein, tea catechins, fiber derives from Psyllium 
Seed husk, chitosan, low-molecular weight sodium alginate, and S-methylcysteine 
sulfoxide in Broccoli & cabbage. S-methylcysteine sulfoxide decreases blood LDL 
cholesterol concentration by enhancing the exchange from cholesterol to bile acids. 
Chitosan decreases blood LDL cholesterol concentration by the inhibition of intestinal 
absorption of cholesterol and bile acids. Other ingredients decrease blood LDL 
cholesterol concentration by the inhibition of intestinal cholesterol absorption.  
Based on the numbers of PubMed searches by the term of “clinical trial” (Jan 
19th, 2018), numerous clinical trials regarding PS and soy protein were executed in the 
world. The cholesterol-lowering action of PS seems to be significantly robust compared 
to other ingredients. Thus, the FDA has approved the health claim regarding PS. Plant 
sterol esters: foods containing at least 0.65 g per serving of plant sterol esters, eaten 
twice a day with meals for a daily total intake of at least 1.3 g (0.75 g/day as a free 
form), as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart 
disease. Plant stanol esters: foods containing at least 1.7 g per serving of plant stanol 
esters, eaten twice a day with meals for a total daily intake of at least 3.4 g (2 g/day as a 
free form), as part of a diet low in saturated fat and cholesterol, may reduce the risk of 
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heart disease. Also, the FDA reported that a daily intake of approximately 2 g of PS (as 
free forms) is required to exert a relationship between PS consumption and the 
reduction in CVD risk.  
Although the FOSHUs for PS in Japan have not permitted since 2009, the 
health claims for PS have been spread in other countries such as China and Canada. 
Nowadays, many functional foods enriched with PS are available in EU, U.S., Canada, 
Australia, New Zealand, Japan, China, Taiwan, South Korea, South America, and 
Mexico.    
Meanwhile, on Oct 31th, 2017, the FDA is proposing to revoke the use of health 
claims on the relationship between soy protein and CHD since 1999 on the label or in 
the labeling of foods, because the evidence does not well support the health claim of soy 
protein. Thus, further scientific research for soy protein will be needed to evaluate 
exactly. To extend the human health span worldwide, clinical evidence on the functional 
foods should be verified in different populations. Also, a great deal of thought should be 
given to the real effectiveness of physiological function, as well as basic food features 
such as nutritional and sensory functions, in a daily practical field.  
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Table 6-1  Major ingredients that function to manage high blood cholesterol used for 
FOSHUs in Japan 
Ingredients 
(permitted year) 
Dose (/day) 
Product form 
Mechanism Cholesterol 
reduction (%) 
Number of 
PubMed searches 
by clinical trial 
 (Jan 19th 2018) 
PS  
(1999-2008) 
0.4-0.8 g 
·edible oil 
·margarine 
·mayonnaise 
Inhibition of 
cholesterol 
absorption 
〜10-15% 401 
Soy protein 
(1999-2011) 
6-8 g 
·soy milk 
·soup 
Inhibition of 
cholesterol 
absorption 
〜5-10% 199 
Tea catechins 
(2011-2016) 
197 mg 
·beverage 
Inhibition of 
cholesterol 
absorption 
〜5% 45 
Fiber derives from 
Psyllium Seed 
husk (1999-2010) 
4-4.5 g 
·jelly beverage 
Inhibition of 
cholesterol and bile 
acids absorption 
〜5% 41 
Chitosan 
(2002-2015) 
 
0.9-1 g 
·beverage 
Inhibition of bile 
acids absorption 
〜5-10% 18 
Low-molecular 
weight sodium 
alginate 
(1998-2015) 
4 g 
·beverage 
Inhibition of 
cholesterol 
absorption 
〜5% 3 
(not limited by 
M.W.) 
S-methylcysteine 
sulfoxide in 
broccoli and 
cabbage (2008) 
26 mg 
·jelly beverage 
Increase in bile 
acids synthesis 
〜5% 0 
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6.4  Further prospective research on DAG oil   
 
In the last decade, micro-analytical techniques have advanced. The presences of new 
substances which had never been found in the foods so far have been gradually 
identified. Although glycidol fatty acid esters (GEs) had been unknown contaminants in 
refined edible oils, the German Federal Institute for Risk Assessment (BfR) firstly 
reported in March 2009 that GEs have concern of possible exposure to glycidol (G) 
(2,3-epoxy-1-propanol), an animal carcinogen during digestion (BfR, 2009; Bakhiya et 
al., 2011). In June 2009, Econa Cooking Oil ® (DAG ≥ 80 wt%) produced by Kao 
Corporation in Japan was found to contain trace amounts of GEs as contaminants. Thus, 
although the safety of DAG oil have been previously confirmed in different studies 
(Morita & Soni, 2009) and no alleged safety problems were observed, the company 
temporarily halted the production of the product until GEs levels could be reduced, and 
voluntarily revoked the FOSHU status of the product. Subsequently, because adverse 
effects of DAG oil were not confirmed in animal studies, although DAG oil contains 
GE as contaminants, Food Safety Commission of Japan (FSCJ, 2015) judged that tumor 
promoting risk in human is negligible from the daily consumption of DAG oil in foods. 
The tumor promoting activity of DAG oil, once concerned, was denied. 
Kao Corporation have contributed to the standardization of novel methods to 
quantify GEs (Masukawa et al., 2010; Masukawa et al., 2011; Shiro et al., 2011), the 
evaluations for the toxicity of GEs using genotoxic test (Ikeda et al., 2012) and 
toxicokinetic studies in animal (Wakabayashi et al., 2012) and human (Honda et al., 
2011; Honda et al., 2012), respectively, demonstrating that the safety of DAG oil is 
almost equivalent to that of TAG oil. Also, the reduction technique of GEs has been 
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consistently investigated (Shimizu et al., 2012). Eventually, the GEs content of edible 
oils in Japan is lower level than that of products reported abroad.  
More recent research brings a new insight into the mechanism by which DAG 
oil reduces visceral fat accumulation. Incretins are gut hormones involved with 
postprandial glucose and fat metabolisms. GIP that is produced and secreted by gut K 
cells of the duodenum and jejunum, is a key molecule linked to obesity, especially fat 
uptake into adipocytes. The blood concentration of GIP is elevated in obese type 2 
diabetic patients (Creutzfeldt er al., 1978). It has been reported that DAG oil-containing 
meal possibly lowers postprandial GIP response compared to TAG oil-containing meal, 
suggesting that DAG oil may partly contribute to the prevention of obesity by regulating 
GIP secretion from the gut after meals (Shoji et al., 2012). The physiological effects of 
DAG oil on the gut function should be continuously examined.   
In conclusion, PS/DAG oil has the potential for providing several benefits in 
the cholesterol metabolism (intestinal absorption and hepatic synthesis), blood 
lipoprotein metabolism, fibrinolysis and visceral fat accumulation (Fig. 6-1). PS/DAG 
oil will also work as a practical first-line treatment to ameliorate atherogenic 
lipoproteins such as LDL cholesterol and Lp(a) concentrations before resorting to drug 
treatments and after. PS/DAG oil may be a new lifetime of healthy edible oil for the 
management of high blood cholesterol and obesity at home in various populations to 
prevent CVD (Fig. 6-4). Further research should be explored to confirm the 
effectiveness and safety for longer-term period globally.  
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Fig. 6-4  Effectiveness for consuming PS/DAG oil or DAG oil in different populations   
    Red bars illustrate preventive effects of DAG oil.  
Blue bars illustrate preventive effects of PS/DAG oil. 
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